year,year_approval_count,drug_name,active_ingredient,approval_date,approved_use,drug_link,press_release,drug_trials_snapshot
2012,1,Voraxaze,glucarpidase,2012-01-17,To treat patients with toxic levels of methotrexate in their blood due to kidney failure. Press Release,http://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=125327&SearchType=BasicSearch,,
2012,2,Picato,ingenol mebutate,2012-01-23,For the topical treatment of actinic keratosis.,http://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=202833&SearchType=BasicSearch,,
2012,3,Inlyta,axitinib,2012-01-27,To treat patients with advanced kidney cancer (renal cell carcinoma) who have not responded to another drug for this type of cancer.Press Release,http://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=202324&SearchType=BasicSearch,,
2012,4,Erivedge,vismodegib,2012-01-30,"To treat adult patients with basal cell carcinoma, the most common type of skin cancer.Press Release",http://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=203388&SearchType=BasicSearch,,
2012,5,Kalydeco,ivacaftor,2012-01-31,For the treatment of a rare form of cystic fibrosis (CF) in patients ages 6 years and older who have the specific G551D mutation in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene. Press Release,,,
2012,6,Zioptan,tafluprost,2012-02-10,For reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.Press Release,http://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=202514&SearchType=BasicSearch,,
2012,7,Surfaxin,lucinactant,2012-03-06,"For the prevention of respiratory distress syndrome (RDS), a breathing disorder that affects premature infants.Press Release",http://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=021746&SearchType=BasicSearch,,
2012,8,Omontys,peginesatide,2012-03-27,"To treat anemia, a condition in which the body does not have enough healthy red blood cells, in adult dialysis patients who have chronic kidney disease (CKD).Press Release",http://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=202799&SearchType=BasicSearch,,
2012,9,Amyvid,Florbetapir F 18,2012-04-06,Used as a radioactive diagnostic agent for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline.,http://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=202008&SearchType=BasicSearch,,
2012,10,Stendra,avanafil,2012-04-27,To treat erectile dysfunction.Press Release,http://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=202276&SearchType=BasicSearch,,
2012,11,Elelyso,taliglucerase alfa,2012-05-01,"For long-term enzyme replacement therapy to treat a form of Gaucher disease, a rare genetic disorderPress Release",http://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=022458&SearchType=BasicSearch,,
2012,12,Perjeta,pertuzumab,2012-06-08,To treat patients with HER2-positive late-stage (metastatic) breast cancer.Press Release,http://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=125409&SearchType=BasicSearch,,
2012,13,Belviq,lorcaserin hydrochloride,2012-06-27,For chronic weight management.Press Release,http://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=022529&SearchType=BasicSearch,,
2012,14,Myrbetriq,mirabegron,2012-06-28,To treat adults with overactive bladder.Press Release,http://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=202611&SearchType=BasicSearch,,
2012,15,Prepopik,"sodium picosulfate, magnesium oxide and citric acid",2012-07-16,To help cleanse the colon in adults preparing for colonoscopy.Press Release,http://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=202535&SearchType=BasicSearch,,
2012,16,Kyprolis,carfilzomib,2012-07-20,"To treat patients with multiple myeloma who have received at least two prior therapies, including treatment with Velcade (bortezomib) and an immunomodulatory.Press Release",http://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=202714&SearchType=BasicSearch,,
2012,17,Tudorza Pressair,aclidinium bromide,2012-07-23,"For the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. Press Release",http://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=202450&SearchType=BasicSearch,,
2012,18,Zaltrap,ziv-aflibercept,2012-08-03,"For use in combination with a FOLFIRI (folinic acid, fluorouracil and irinotecan) chemotherapy regimen to treat adults with colorectal cancer. Press Release",http://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=125418&SearchType=BasicSearch,,
2012,19,Stribild,"elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate",2012-08-27,A once-a-day combination pill to treat HIV-1 infection in adults who have never been treated for HIV infection.Press Release,http://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=203100&SearchType=BasicSearch,,
2012,20,Neutroval,tbo-filgrastim,2012-08-29,"To reduce the time certain patients receiving cancer chemotherapy experience severe neutropenia, a decrease in infection-fighting white blood cells called neutrophils.Press Release",http://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=125294&SearchType=BasicSearch,,
2012,21,Linzess,linaclotide,2012-08-30,To treat chronic idiopathic constipation and to treat irritable bowel syndrome with constipation (IBS-C) in adults. Press Release,,,
2012,22,Xtandi,enzalutamide,2012-08-31,"To treat men with late-stage (metastatic) castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone.Press Release",http://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=203415&SearchType=BasicSearch,,
2012,23,Bosulif,bosutinib,2012-09-04,"To treat chronic myelogenous leukemia (CML), a blood and bone marrow disease that usually affects older adults.Press Release",http://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=203341&SearchType=BasicSearch,,
2012,24,Aubagio,teriflunomide,2012-09-12,For the treatment of adults with relapsing forms of multiple sclerosis (MS).Press Release,http://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=202992&SearchType=BasicSearch,,
2012,25,Choline C 11 Injection,Choline C 11 Injection,2012-09-12,A Positron Emission Tomography (PET) imaging agent used to help detect recurrent prostate cancer.Press Release,http://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=203155&SearchType=BasicSearch,,
2012,26,Stivarga,regorafenib,2012-09-27,To treat patients with colorectal cancer that has progressed after treatment and spread to other parts of the body (metastatic).Press Release,http://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=203085&SearchType=BasicSearch,,
2012,27,Jetrea,ocriplasmin,2012-10-17,To treat an eye condition called symptomatic vitreomacular adhesion (VMA).Press Release,http://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=125422&SearchType=BasicSearch,,
2012,28,Fycompa,perampanel,2012-10-22,To treat partial onset seizures in patients with epilepsy ages 12 years and older.Press Release,http://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=202834&SearchType=BasicSearch,,
2012,29,Synribo,omacetaxine mepesuccinate,2012-10-26,"To treat adults with chronic myelogenous leukemia (CML), a blood and bone marrow disease.Press Release",http://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=203585&SearchType=BasicSearch,,
2012,30,Xeljanz,tofacitinib,2012-11-06,"To treat adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to, or who are intolerant of, methotrexate.Press Release",http://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=203214&SearchType=BasicSearch,,
2012,31,Cometriq,cabozantinib,2012-11-29,To treat medullary thyroid cancer that has spread to other parts of the body (metastasized).Press Release,http://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=203756&SearchType=BasicSearch,,
2012,32,Iclusig,ponatinib,2012-12-14,"To treat adults with chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), two rare blood and bone marrow diseases.Press Release",http://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=203469&SearchType=BasicSearch,,
2012,33,raxibacumab,raxibacumab,2012-12-14,"To treat inhalational anthrax, a form of the infectious disease caused by breathing in the spores of the bacterium Bacillus anthracis. Press Release",http://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=125349&SearchType=BasicSearch,,
2012,34,Signifor,pasereotide,2012-12-14,To treat Cushing’s disease patients who cannot be helped through surgeryPress Release,http://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=200677&SearchType=BasicSearch,,
2012,35,Gattex,teduglutide,2012-12-21,To treat adults with short bowel syndrome (SBS) who need additional nutrition from intravenous feeding (parenteral nutrition).Press Release,http://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=203441&SearchType=BasicSearch,,
2012,36,Juxtapid,lomitapide,2012-12-21,"To reduce low-density lipoprotein (LDL) cholesterol, total cholesterol, apolipoprotein B, and non-high-density lipoprotein (non-HDL) cholesterol in patients with homozygous familial hypercholesterolemia (HoFH). Press Release",http://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=203858&SearchType=BasicSearch,,
2012,37,Eliquis,apixaban,2012-12-28,To reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problem.Press Release,http://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=202155&SearchType=BasicSearch,,
2012,38,Sirturo,bedaquiline,2012-12-28,As part of combination therapy to treat adults with multi-drug resistant pulmonary tuberculosis (TB) when other alternatives are not available.Press Release,http://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=204384&SearchType=BasicSearch,,
2012,39,Fulyzaq,crofelemer,2012-12-31,"To treat HIV/AIDS patients whose diarrhea is not caused by an infection from a virus, bacteria, or parasite. Press Release",http://wayback.archive-it.org/7993/20161022052138/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=202292&SearchType=BasicSearch,,
2013,1,Nesina,alogliptin,2013-01-25,To improve blood sugar control in adults with type 2 diabetes.Press Release,http://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=022271&SearchType=BasicSearch,,
2013,2,Kynamro,mipomersen sodium,2013-01-29,To treat patients with a rare type of high cholesterol called homozygous familial hypercholesterolemia (HoFH). Press Release,http://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=203568&SearchType=BasicSearch,,
2013,3,Pomalyst,pomalidomide,2013-02-08,To treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs.Press Release,http://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=204026&SearchType=BasicSearch,,
2013,4,Kadcyla,ado-trastuzumab emtansine,2013-02-22,"For patients with HER2-positive, late-stage (metastatic) breast cancer.Press Release",http://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=125427&SearchType=BasicSearch,,
2013,5,Osphena,ospemifene,2013-02-26,"To treat women experiencing moderate to severe dyspareunia (pain during sexual intercourse), a symptom of vulvar and vaginal atrophy due to menopause.Press Release",http://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=203505&SearchType=BasicSearch,,
2013,6,Lymphoseek,technetium Tc 99m tilmanocept,2013-03-13,A radioactive diagnostic imaging agent that helps doctors locate lymph nodes in patients with breast cancer or melanoma who are undergoing surgery to remove tumor-draining lymph nodes.Press Release,http://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=202207&SearchType=BasicSearch,,
2013,7,Dotarem,gadoterate meglumine,2013-03-20,"For use in magnetic resonance imaging (MRI) of the brain, spine and associated tissues of patients ages 2 years and older.Press Release",http://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=204781&SearchType=BasicSearch,,
2013,8,Tecfidera,dimethyl fumarate,2013-03-27,To treat adults with relapsing forms of multiple sclerosis (MS).Press Release,http://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=204063&SearchType=BasicSearch,,
2013,9,Invokana,canagliflozin,2013-03-29,"Used with diet and exercise, to improve glycemic control in adults with type 2 diabetes.Press Release",http://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=204042&SearchType=BasicSearch,,
2013,10,Breo Ellipta,fluticasone furoate and vilanterol inhalation powder,2013-05-10,"For the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.Press Release",http://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=204275&SearchType=BasicSearch,,
2013,11,Xofigo,radium Ra 223 dichloride,2013-05-15,To treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs.Press Release,http://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=203971&SearchType=BasicSearch,,
2013,12,Tafinlar,dabrafenib,2013-05-29,To treat patients with melanoma whose tumors express the BRAF V600E gene mutation.Press Release,http://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=202806&SearchType=BasicSearch,,
2013,13,Mekinist,trametinib,2013-05-29,To treat patients whose tumors express the BRAF V600E or V600K gene mutations. Press Release,http://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=204114&SearchType=BasicSearch,,
2013,14,Gilotrif,afatinib,2013-07-12,"For patients with late stage (metastatic) non-small cell lung cancer (NSCLC) whose tumors express specific types of epidermal growth factor receptor (EGFR) gene mutations, as detected by an FDA-approved test. Press Release",http://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=201292&SearchType=BasicSearch,,
2013,15,Tivicay,dolutegravir,2013-08-12,To treat HIV-1 infection.Press Release,http://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=204790&SearchType=BasicSearch,,
2013,16,Brintellix,vortioxetine,2013-09-30,To treat adults with major depressive disorder.Press Release,http://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=204447&SearchType=BasicSearch,,
2013,17,Duavee,conjugated estrogens/bazedoxifene,2013-10-03,To treat moderate-to-severe hot flashes (vasomotor symptoms) associated with menopause and to prevent osteoporosis after menopause.Web Posting,http://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=022247&SearchType=BasicSearch,,
2013,18,Adempas,riociguat,2013-10-08,To treat adults with two forms of pulmonary hypertension.Press Release,http://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=204819&SearchType=BasicSearch,,
2013,19,Opsumit,macitentan,2013-10-18,"To treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive and debilitating disease that can lead to death or the need for lung transplantation.Press Release",http://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=204410&SearchType=BasicSearch,,
2013,20,Vizamyl,flutemetamol F 18 injection,2013-10-25,A radioactive diagnostic drug for use with positron emission tomography (PET) imaging of the brain in adults being evaluated for Alzheimer's disease (AD) and dementia.Press Release,http://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=203137&SearchType=BasicSearch,,
2013,21,Gazyva,obinutuzumab,2013-11-01,For use in combination with chlorambucil to treat patients with previously untreated chronic lymphocytic leukemia (CLL).Press Release,http://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=125486&SearchType=BasicSearch,,
2013,22,Aptiom,eslicarbazepine acetate,2013-11-08,As an add-on medication to treat seizures associated with epilepsy.Press Release,http://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=022416&SearchType=BasicSearch,,
2013,23,Imbruvica,ibrutinib,2013-11-13,"To treat patients with mantle cell lymphoma (MCL), a rare and aggressive type of blood cancer.Press Release",http://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=205552&SearchType=BasicSearch,,
2013,24,Luzu,luliconozole,2013-11-14,"For the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum, in patients 18 years of age and older.",http://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=204153&SearchType=BasicSearch,,
2013,25,Olysio,simeprevir,2013-11-22,To treat chronic hepatitis C virus infection.Press Release,http://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=205123&SearchType=BasicSearch,,
2013,26,Sovaldi,sofosbuvir,2013-12-06,To treat chronic hepatitis C virus (HCV) infection.Press Release,http://wayback.archive-it.org/7993/20161022052135/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&searchTerm=204671&SearchType=BasicSearch,,
2013,27,Anoro Ellipta,umeclidinium and vilanterol inhalation powder,2013-12-18,"For the once-daily, long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).Press Release",,,
2014,1,Farxiga,dapaglifozin,2014-01-08,"To improve glycemic control, along with diet and exercise, in adults with type 2 diabetesPress Release",http://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=202293&DrugName=FARXIGA&ActiveIngred=DAPAGLIFLOZIN&SponsorApplicant=BRISTOL%20MYERS%20SQUIBB&ProductMktStatus=1&goto=Search.DrugDetails,,
2014,2,Hetlioz,tasimelteon,2014-01-31,To treat non-24- hour sleep-wake disorder (“non-24”) in totally blind individuals. Non-24 is a chronic circadian rhythm (body clock) disorder in the blind that causes problems with the timing of sleep.Press Release,http://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=205677&DrugName=HETLIOZ&ActiveIngred=TASIMELTEON&SponsorApplicant=VANDA%20PHARMACEUTICALS%20INC&ProductMktStatus=1&goto=Search.DrugDetails,,
2014,3,Vimizim,elosulfase alfa,2014-02-14,Treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome)Press Release,http://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=125460&DrugName=VIMIZIM&ActiveIngred=ELOSULFASE%20ALFA&SponsorApplicant=BIOMARIN%20PHARM&ProductMktStatus=1&goto=Search.DrugDetails,,
2014,4,Northera,droxidopa,2014-02-18,To treat neurogenic orthostatic hypotension (NOH)Press Release,http://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=203202&DrugName=NORTHERA&ActiveIngred=DROXIDOPA&SponsorApplicant=CHELSEA%20THERAPS%20INC&ProductMktStatus=1&goto=Search.DrugDetails,,
2014,5,Myalept,metreleptin for injection,2014-02-24,To treat the complications of leptin deficiencyPress Release,http://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=125390&DrugName=MYALEPT&ActiveIngred=METRELEPTIN&SponsorApplicant=AMYLIN%20PHARMS%20LLC&ProductMktStatus=1&goto=Search.DrugDetails,,
2014,6,Neuraceq,florbetaben F 18 injection,2014-03-19,For Positron EmissionTomography (PET) imaging of the brain,http://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=204677&DrugName=NEURACEQ&ActiveIngred=FLORBETABEN%20F%2D18&SponsorApplicant=PIRAMAL%20IMAGING&ProductMktStatus=1&goto=Search.DrugDetails,,
2014,7,Impavido,miltefosine,2014-03-19,To treat a tropical disease called leishmaniasisPress Release,http://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=204684&DrugName=IMPAVIDO&ActiveIngred=MILTEFOSINE&SponsorApplicant=PALADIN%20THERAP&ProductMktStatus=1&goto=Search.DrugDetails,,
2014,8,Otezla,apremilast,2014-03-21,To treat adults with active psoriatic arthritis (PsA)Press Release,http://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=205437&DrugName=OTEZLA&ActiveIngred=APREMILAST&SponsorApplicant=CELGENE%20CORP&ProductMktStatus=1&goto=Search.DrugDetails,,
2014,9,Tanzeum,albiglutide,2014-04-15,"To improve glycemic control, along with diet and exercise, in adults with type 2 diabetesPress Release",http://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=125431&DrugName=TANZEUM&ActiveIngred=ALBIGLUTIDE&SponsorApplicant=GLAXOSMITHKLINE%20LLC&ProductMktStatus=1&goto=Search.DrugDetails,,
2014,10,Cyramza,ramucirumab,2014-04-21,To treat patients with advanced stomach cancer or gastroesophageal junction adenocarcinomaPress Release,http://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=125477&DrugName=CYRAMZA&ActiveIngred=RAMUCIRUMAB&SponsorApplicant=ELI%20LILLY%20AND%20CO&ProductMktStatus=1&goto=Search.DrugDetails,,
2014,11,Sylvant,siltuximab,2014-04-23,"To treat patients with multicentric Castleman’s disease (MCD), a rare disorder similar to lymphoma (cancer of the lymph nodes)Press Release",http://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=125496&DrugName=SYLVANT&ActiveIngred=SILTUXIMAB&SponsorApplicant=JANSSEN%20BIOTECH&ProductMktStatus=1&goto=Search.DrugDetails,,
2014,12,Zykadia,ceritinib,2014-04-29,To treat patients with a certain type of late-stage (metastatic) non-small cell lung cancer (NSCLC)Press Release,http://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=205755&DrugName=ZYKADIA&ActiveIngred=CERITINIB&SponsorApplicant=NOVARTIS%20PHARMS&ProductMktStatus=1&goto=Search.DrugDetails,,
2014,13,Zontivity,vorapaxar,2014-05-08,To reduce the risk of heart attacks and stroke in high-risk patientsPress Release,http://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=204886&DrugName=ZONTIVITY&ActiveIngred=VORAPAXAR%20SULFATE&SponsorApplicant=MERCK%20SHARP%20DOHME&ProductMktStatus=1&goto=Search.DrugDetails,,
2014,14,Entyvio,vedolizumab,2014-05-20,To treat adult patients with moderate to severe ulcerative colitis and adult patients with moderate to severe Crohn‘s diseasePress ReleaseDrug Trials Snapshot (Crohn's Disease)Drug Trials Snapshot (ulcerative colitis),http://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=125476&DrugName=ENTYVIO&ActiveIngred=VEDOLIZUMAB&SponsorApplicant=TAKEDA%20PHARMS%20USA&ProductMktStatus=1&goto=Search.DrugDetails,,
2014,15,Dalvance,dalbavancin,2014-05-23,To treat adults with skin infectionsPress Release Drug Trials Snapshot,http://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=021883&DrugName=DALVANCE&ActiveIngred=DALBAVANCIN%20HYDROCHLORIDE&SponsorApplicant=DURATA%20THERAPS%20INTL&ProductMktStatus=1&goto=Search.DrugDetails,,
2014,16,Jublia,efinaconazole,2014-06-06,Treat mild to moderate onychomycosis (fungal infection) No Press ReleaseDrug Trials Snapshot,http://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=203567&DrugName=JUBLIA&ActiveIngred=EFINACONAZOLE&SponsorApplicant=DOW%20PHARM&ProductMktStatus=1&goto=Search.DrugDetails,,
2014,17,Sivextro (tablet)Sivextro (injection),tedizolid phosphate,2014-06-20,To treat adults with skin infectionsPress ReleaseDrug Trials Snapshot,http://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=205435&DrugName=SIVEXTRO&ActiveIngred=TEDIXOLID%20PHOSPHATE&SponsorApplicant=CUBIST%20PHARMS&ProductMktStatus=1&goto=Search.DrugDetails,,
2014,18,Beleodaq,belinostat,2014-07-03,To treat patients with peripheral T-cell lymphoma (PTCL) Press Release,http://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=206256&DrugName=BELEODAQ&ActiveIngred=BELINOSTAT&SponsorApplicant=SPECTRUM%20PHARMS&ProductMktStatus=1&goto=Search.DrugDetails,,
2014,19,Kerydin,tavaborole,2014-07-07,For the topical treatment of onychomycosis of the toenails (No Press Release),http://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=204427&DrugName=KERYDIN&ActiveIngred=TAVABOROLE&SponsorApplicant=ANACOR%20PHARMS%20INC&ProductMktStatus=1&goto=Search.DrugDetails,,
2014,20,Zydelig,idelalisib,2014-07-23,To treat patients with trhee types of blood cancersPress Release,http://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=206545&DrugName=ZYDELIG&ActiveIngred=IDELALISIB&SponsorApplicant=GILEAD%20SCIENCES%20INC&ProductMktStatus=1&goto=Search.Label_ApprovalHistory,,
2014,21,Striverdi Respimat,olodaterol,2014-07-31,To treat chronic obstructive pulmonary diseasePress Release,http://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=203108&DrugName=Striverdi%20Respimat&ActiveIngred=Olodaterol%20Respimat&SponsorApplicant=BOEHRINGER%20INGELHEIM&ProductMktStatus=1&goto=Search.Label_ApprovalHistory,,
2014,22,Jardiance,empagliflozin,2014-08-01,To improve gylcemic control in adults with type 2 diabetesPress Release,http://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=204629&DrugName=JARDIANCE&ActiveIngred=EMPAGLIFLOZIN&SponsorApplicant=BOEHRINGER%20INGELHEIM&ProductMktStatus=1&goto=Search.DrugDetails,,
2014,23,Orbactiv,oritavancin,2014-08-06,To treat adults with skin infectionsPress Release,http://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=206334&DrugName=ORBACTIV&ActiveIngred=ORITAVANCIN%20DIPHOSPHATE&SponsorApplicant=MEDICINES%20CO&ProductMktStatus=1&goto=Search.DrugDetails,,
2014,24,Belsomra,suvorexant,2014-08-13,To treat difficulty in falling and staying asleep (insomnia)Press Release,http://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=204569&DrugName=BELSOMRA&ActiveIngred=SUVOREXANT&SponsorApplicant=MERCK%20AND%20CO%20INC&ProductMktStatus=1&goto=Search.DrugDetails,,
2014,25,Plegridy,peginterferon beta-1a,2014-08-15,For the treatment of patients with relapsing forms of multiple sclerosis,http://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=125499&DrugName=PLEGRIDY&ActiveIngred=PEGINTERFERON%20BETA%2D1A&SponsorApplicant=BIOGEN%20IDEC%20INC&ProductMktStatus=1&goto=Search.DrugDetails,,
2014,26,Cerdelga,eliglustat,2014-08-19,For the long-term treatment of adult patients with the Type 1 form of Gaucher diseasePress Release,http://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=205494&DrugName=CERDELGA&ActiveIngred=ELIGLUSTAT&SponsorApplicant=GENZYME%20CORP&ProductMktStatus=1&goto=Search.DrugDetails,,
2014,27,Keytruda,pembrolizumab,2014-09-04,For treatment of patients with advanced or unresectable melanoma who are no longer responding to other drugs.Press Release,http://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=125514&DrugName=KEYTRUDA&ActiveIngred=PEMBROLIZUMAB&SponsorApplicant=MERCK%20SHARP%20DOHME&ProductMktStatus=1&goto=Search.Label_ApprovalHistory,,
2014,28,Movantik,naloxegol,2014-09-16,To treat opioid-induced constipation in adults with chronic non-cancer pain.Press Release,http://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=204760&DrugName=MOVANTIK&ActiveIngred=NALOXEGOL&SponsorApplicant=ASTRAZENECA%20PHARMS&ProductMktStatus=1&goto=Search.DrugDetails,,
2014,29,Trulicity,dulaglutide,2014-09-18,To treat adults with type 2 diabetes.Press Release,http://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=125469&DrugName=TRULICITY&ActiveIngred=DULAGLUTIDE&SponsorApplicant=ELI%20LILLY%20AND%20CO&ProductMktStatus=1&goto=Search.DrugDetails,,
2014,30,Harvoni,ledipasvir/sofosbuvir,2014-10-10,To treat chronic hepatitis C virus (HCV) genotype 1 infectionPress Release,http://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=205834&DrugName=HARVONI&ActiveIngred=LEDIPASVIR%3B%20SOFOSBUVIR&SponsorApplicant=GILEAD%20SCIENCES%20INC&ProductMktStatus=1&goto=Search.DrugDetails,,
2014,31,Akynzeo,netupitant and palonosetron,2014-10-10,To treat nausea and vomiting in patients undergoing cancer chemotherapyPress Release,http://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=205718&DrugName=AKYNZEO&ActiveIngred=NETUPITANT%3B%20PALONOSETRON%20HYDROCHLORIDE&SponsorApplicant=HELSINN%20HLTHCARE&ProductMktStatus=1&goto=Search.DrugDetails,,
2014,32,Lumason,sulfur hexafluoride lipid microsphere,2014-10-10,For patients whose ultrasound image of the heart (echocardiograms) are hard to see with ultrasound wavesPress Release,http://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=203684&DrugName=LUMASON&ActiveIngred=SULFUR%20HEXAFLUORIDE%20LIPID%2DTYPE%20A%20MICROSPHERES&SponsorApplicant=BRACCO&ProductMktStatus=1&goto=Search.DrugDetails,,
2014,33,Ofev,nintedanib,2014-10-15,For the treatment of idiopathic pulmonary fibrosis (IPF)Press Release,http://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=205832&DrugName=OFEV&ActiveIngred=NINTEDANIB&SponsorApplicant=BOEHRINGER%20INGELHEIM&ProductMktStatus=1&goto=Search.DrugDetails,,
2014,34,Esbriet,pirfenidone,2014-10-15,For the treatment of idiopathic pulmonary fibrosis (IPF)Press Release,http://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=022535&DrugName=ESBRIET&ActiveIngred=PIRFENIDONE&SponsorApplicant=INTERMUNE%20INC&ProductMktStatus=1&goto=Search.DrugDetails,,
2014,35,Blincyto,blinatumomab,2014-12-03,To treat patients with Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia (B-cell ALL)Press Release,http://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=125557&DrugName=BLINCYTO&ActiveIngred=BLINATUMOMAB&SponsorApplicant=AMGEN&ProductMktStatus=1&goto=Search.Label_ApprovalHistory,,
2014,36,Xtoro,finafloxacin otic suspension,2014-12-17,"To treat acute otitis externa, commonly known as swimmer’s earPress Release",http://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=206307&DrugName=XTORO&ActiveIngred=FINAFLOXACIN&SponsorApplicant=ALCON%20RES%20LTD&ProductMktStatus=1&goto=Search.Label_ApprovalHistory,,
2014,37,Lynparza,olaparib,2014-12-19,To treat advanced ovarian cancerPress Release,http://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=206162&DrugName=LYNPARZA&ActiveIngred=OLAPARIB&SponsorApplicant=ASTRAZENECA%20LP&ProductMktStatus=1&goto=Search.Label_ApprovalHistory,,
2014,38,Viekira Pak,"(ombitasvir, paritaprevir and ritonavir tablets co-packaged with dasabuvir tablets)",2014-12-19,"To treat patients with chronic hepatitis C virus (HCV) genotype 1 infection, including those with a type of advanced liver disease called cirrhosisPress Release",http://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=206619&DrugName=VIEKIRA%20PAK&ActiveIngred=OMBITASIVR%3B%20PARITAPREVIR%3B%20RITONAVIR%3B%20DASABUVIR&SponsorApplicant=ABBVIE%20INC&ProductMktStatus=1&goto=Search.Label_ApprovalHistory,,
2014,39,Zerbaxa,ceftolozane/tazobactam,2014-12-19,To treat adults with complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI)Press Release,http://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=206829&DrugName=ZERBAXA&ActiveIngred=CEFTOLOZANE%3BTAZOBACTAM&SponsorApplicant=CUBIST%20PHARMS%20INC&ProductMktStatus=1&goto=Search.Label_ApprovalHistory,,
2014,40,Rapivab,peramivir,2014-12-19,To treat influenza infection in adultsPress Release,http://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=206426&DrugName=RAPIVAB&ActiveIngred=PERAMIVIR&SponsorApplicant=BIOCRYST%20PHARMACEUTICALS%20INC&ProductMktStatus=1&goto=Search.DrugDetails,,
2014,41,Opdivo,nivolumab,2014-12-22,To treat patients with unresectable (cannot be removed by surgery) or metastatic (advanced) melanoma who no longer respond to other drugsPress Release,http://wayback.archive-it.org/7993/20161022052129/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=125554&DrugName=OPDIVO&ActiveIngred=NIVOLUMAB&SponsorApplicant=BRISTOL%20MYERS%20SQUIBB&ProductMktStatus=1&goto=Search.DrugDetails,,
2015,1,Savaysa,edoxaban,2015-01-08,To reduce the risk of stroke and dangerous blood clots (systemic embolism) in patients with atrial fibrillation that is not caused by a heart valve problemDrug Trials Snapshot (atrial fibrillation) Drug Trials Snapshot (venous thromboembolism),http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206316,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-savaysa-edoxaban-treatment-venous-thromboembolism-vte
2015,2,Cosentyx,secukinumab,2015-01-21,To treat adults with moderate-to-severe plaque psoriasisDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125504,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-cosentyx-secukinumab
2015,3,Natpara,parathyroid horomone,2015-01-23,To control hypocalcemia (low blood calcium levels) in patients with hypoparathyroidismDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125511,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-natpara-parathyroid-hormone
2015,4,Ibrance,palbociclib,2015-02-03,To treat advanced (metastatic) breast cancerDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207103,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-ibrance-palbociclib
2015,5,Lenvima,lenvatinib,2015-02-13,"To treat patients with progressive, differentiated thyroid cancer (DTC) whose disease progressed despite receiving radioactive iodine therapy (radioactive iodine refractory disease).Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206947,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-lenvima
2015,6,Farydak,panobinostat,2015-02-23,To treat patients with multiple myelomaDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205353,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-farydak-panobinostat
2015,7,Avycaz,ceftazidime-avibactam,2015-02-25,"To treat adults with complicated intra-abdominal infections (cIAI), in combination with metronidazole, and complicated urinary tract infections (cUTI), including kidney infections (pyelonephritis), who have limited or no alternative treatment options.Drug Trials Snaphot (cIAI)",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206494,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-avycaz-ciai
2015,8,Cresembacapsuleinjection,isavuconazonium sulfate,2015-03-06,"To treat adults with invasive aspergillosis and invasive mucormycosis, rare but serious infectionsDrug Trials Snapshot (aspergillosis)Drug Trials Snapshot (mucormycosis)",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207500,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-cresemba-mucormycosis
2015,9,Unituxin,dinutuximab,2015-03-10,To treat pediatric patients with high-risk neuroblastomaDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125516,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-unituxin
2015,10,Cholbam,cholic acid,2015-03-17,"To treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for patients with peroxisomal disordersDrug Trials Snapshot (bile acid synthesis disorders)Drug Trials Snapshot (peroxisomal disorders)",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205750,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-cholbam-peroxisomal-disorders
2015,11,Corlanor,ivabradine,2015-04-15,To reduce hospitalization from worsening heart failure.Drug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206143,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-corlanor
2015,12,Kybella,deoxycholic acid,2015-04-29,"To treat adults with moderate-to-severe fat below the chin, known as submental fatDrug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206333,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-kybella
2015,13,Viberzi,eluxadoline,2015-05-27,To treat irritable bowel syndrome with diarrhea (IBS-D) in adult men and women.Drug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206940,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-viberzi
2015,14,Kengreal,cangrelor,2015-06-22,To prevent the formation of harmful blood clots in the coronary arteries for adult patients undergoing percutaneous coronary interventionDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=204958,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-kengreal
2015,14,Kengreal,canegrelor,2015-06-22,To prevent the formation of harmful blood clots in the coronary arteries for adult patients undergoing percutaneous coronary intervention Press ReleaseDrug Trials Snapshot,http://wayback.archive-it.org/7993/20161022052128/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=204958&DrugName=KENGREAL&ActiveIngred=CANGRELOR&SponsorApplicant=MEDICINES%20CO&ProductMktStatus=1&goto=Search.DrugDetails,,
2015,15,Orkambi,lumacaftor 200 mg/ivacaftor 125 mg,2015-07-02,To treat cystic fibrosisDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206038,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-orkambi
2015,16,Entresto,sacubitril/valsartan,2015-07-07,To treat heart failureDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207620,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-entresto
2015,17,Rexulti,brexpiprazole,2015-07-10,To treat schizophrenia and as an add on to an antidepressant to treat major depressive disorderDrug Trials Snapshot (treatment of major depressive disorder)Drug Trials Snapshot (treatment of schizophrenia),http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205422,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-rexulti-treatment-schizophrenia
2015,18,Praluent,alirocumab,2015-07-24,To treat certain patients with high cholesterolDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125559,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-praluent
2015,19,Odomzo,sonidegib,2015-07-24,"To treat patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy, or who are not candidates for surgery or radiation therapy.Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205266,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-odomzo
2015,20,Daklinza,daclatasvir,2015-07-24,To treat chronic hepatitis C virus (HCV) genotype 3 infectionsDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206843,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-daklinza
2015,21,Addyi,flibanserin,2015-08-18,"To treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal womenDrug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022526,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-addyi
2015,22,Repatha,evolocumab,2015-08-27,To treat certain patients with high cholesterolDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125522,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-repatha
2015,23,Varubi,rolapitant,2015-09-01,To prevent delayed phase chemotherapy-induced nausea and vomiting (emesis)Drug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206500,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-varubi
2015,24,Xuriden,uridine triacetate,2015-09-04,To treat patients with hereditary orotic aciduriaDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208169,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-xuriden
2015,25,Vraylar,cariprazine,2015-09-17,To treat schizophrenia and bipolar disorder in adultsDrug Trials Snapshot for the treatment of bipolar disorderDrug Trials Snapshot for the treatment of schizophrenia,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=204370,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-vraylar-treatment-schizophrenia
2015,26,Lonsurf,trifluridine and tipiracil,2015-09-22,To treat patients with an advanced form of colorectal cancer who are no longer responding to other therapiesDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207981,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-lonsurf
2015,27,Tresiba,insulin degludec injection,2015-09-25,To improve blood sugar (glucose) control in adults with diabetes mellitusDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=203314,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-tresiba
2015,28,Aristada,aripiprazole lauroxil,2015-10-05,To treat adults with schizophreniaDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207533,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-aristada
2015,29,Praxbind,idarucizumab,2015-10-16,For use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa’s blood-thinning effects.Drug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761025,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-praxbind
2015,30,Veltassa,patiromer for oral suspension,2015-10-21,"To treat hyperkalemia, a serious condition in which the amount of potassium in the blood is too high.Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205739,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-veltassa
2015,31,Yondelis,trabectedin,2015-10-23,To treat specific soft tissue sarcomas (STS) – liposarcoma and leiomyosarcoma – that cannot be removed by surgery (unresectable) or is advanced (metastatic). Drug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207953,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-yondelis
2015,32,Strensiq,asfotase alfa,2015-10-23,"To treat perinatal, infantile and juvenile-onset hypophosphatasia (HPP).Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125513,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-strensiq
2015,33,Nucala,mepolizumab,2015-11-04,For use with other asthma medicines for the maintenance treatment of asthma in patients age 12 years and older.Drug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125526,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-nucala
2015,34,Genvoya,"a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide",2015-11-05,For use as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and olderDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207561,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-genvoya
2015,35,Cotellic,cobimetinib,2015-11-10,"To be used in combination with vemurafenib to treat advanced melanoma that has spread to other parts of the body or can’t be removed by surgery, and that has a certain type of abnormal gene (BRAF V600E or V600K mutation)Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206192,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-cotellic
2015,36,Tagrisso,osimertinib,2015-11-13,To treat certain patients with non-small cell lung cancerDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208065,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-tagrisso
2015,37,Darzalex,daratumumab,2015-11-16,To treat patients with multiple myeloma who have received at least three prior treatments.Drug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761036,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-darzalex
2015,38,Ninlaro,ixazomib,2015-11-20,To treat people with multiple myeloma who have received at least one prior therapyDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208462,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-ninlaro
2015,39,Portrazza,necitumumab,2015-11-24,To treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received medication specifically for treating their advanced lung cancerDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125547,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-portrazza
2015,40,Empliciti,elotuzumab,2015-11-30,To treat people with multiple myeloma who have received one to three prior medicationsDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761035,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-empliciti
2015,41,Kanuma,sebelipase alfa,2015-12-08,To treat patients with a rare disease known as lysosomal acid lipase (LAL) deficiencyDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125561,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-kanuma
2015,42,Alecensa,alectinib,2015-12-11,To treat ALK-positive lung cancerDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208434,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-alecensa
2015,43,Bridion,sugammadex,2015-12-15,To reverse effects of neuromuscular blocking drugs used during surgeryDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022225,,
2015,44,Uptravi,selexipag,2015-12-21,To treat pulmonary arterial hypertensionDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207947,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-uptravi
2015,45,Zurampic,lesinurad,2015-12-22,To treat high blood uric acid levels associated with goutDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207988,,
2016,1,Zepatier,elbasvir and grazoprevir,2016-01-28,To treat patients with chronic hepatitis C virus (HCV) genotypes 1 and 4 infections in adult patients.Press ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208261,https://www.fda.gov/news-events/press-announcements/fda-approves-zepatier-treatment-chronic-hepatitis-c-genotypes-1-and-4,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-zepatier
2016,2,Briviact,brivaracetam,2016-02-18,To treat partial onset seizures in patients age 16 years and older with epilepsy.Press ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205836,https://www.fda.gov/news-events/press-announcements/fda-approves-briviact-treat-partial-onset-seizures,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-briviact
2016,3,Anthim,obiltoxaximab,2016-03-18,To treat inhalational anthrax in combination with appropriate antibacterial drugs.Press ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125509,https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-inhalation-anthrax,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-praluent
2016,4,Taltz,ixekizumab,2016-03-22,To treat adults with moderate-to-severe plaque psoriasis. Press ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=125521,https://www.fda.gov/news-events/press-announcements/fda-approves-new-psoriasis-drug-taltz,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-taltz
2016,5,Cinqair,reslizumab,2016-03-23,To treat severe asthmaPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761033,https://www.fda.gov/news-events/press-announcements/fda-approves-cinqair-treat-severe-asthma,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-cinqair
2016,6,Defitelio,defibrotide sodium,2016-03-30,To treat adults and children who develop hepatic veno-occlusive disease with additional kidney or lung abnormalities after they receive a stem cell transplant from blood or bone marrow called hematopoietic stem cell transplantationPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208114,https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-rare-disease-patients-who-receive-stem-cell-transplant-blood-or-bone,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-defitelio
2016,7,Venclexta,venetoclax,2016-04-11,For chronic lymphocytic leukemia in patients with a specific chromosomal abnormalityPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208573,https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-chronic-lymphocytic-leukemia-patients-specific-chromosomal-abnormality,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-venclexta
2016,8,Nuplazid,pimavanserin,2016-04-29,To treat hallucinations and delusions associated with psychosis experienced by some people with Parkinson’s diseasePress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207318,https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-hallucinations-and-delusions-associated-parkinsons-disease,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-nuplazid
2016,9,Tecentriq,atezolizumab,2016-05-18,"To treat urothelial carcinoma, the most common type of bladder cancerPress ReleaseDrug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761034,https://www.fda.gov/news-events/press-announcements/fda-approves-new-targeted-treatment-bladder-cancer,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-tecentriq
2016,10,Zinbryta,daclizumab,2016-05-27,To treat multiple sclerosisPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761029,https://www.fda.gov/news-events/press-announcements/fda-approves-zinbryta-treat-multiple-sclerosis,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-zinbryta
2016,11,Ocaliva,obeticholic acid,2016-05-27,"To treat rare, chronic liver diseasePress releaseDrug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207999,https://www.fda.gov/news-events/press-announcements/fda-approves-ocaliva-rare-chronic-liver-disease,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-ocaliva
2016,12,Axumin,fluciclovine F 18,2016-05-27,A  new diagnostic imaging agent to detect recurrent prostate cancerPress releaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208054,https://www.fda.gov/news-events/press-announcements/fda-approves-new-diagnostic-imaging-agent-detect-recurrent-prostate-cancer,
2016,13,NETSPOT,gallium Ga 68 dotatate,2016-06-01,A diagnostic imaging agent to detect rare neuroendocrine tumorsPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208547,https://www.fda.gov/news-events/press-announcements/fda-approves-new-diagnostic-imaging-agent-detect-rare-neuroendocrine-tumors,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-netspot
2016,14,Epclusa,sofosbuvir and velpatasvir,2016-06-28,To treat all six major forms of hepatitis C virusPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208341,https://www.fda.gov/news-events/press-announcements/fda-approves-epclusa-treatment-chronic-hepatitis-c-virus-infection,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-epclusa
2016,15,Xiidra,lifitegrast ophthalmic solution,2016-07-11,To treat the signs and symptoms of dry eye diseasePress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208073,https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-dry-eye-disease,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-xiidra
2016,16,Adlyxin,lixisenatide,2016-07-27,To improve glycemic control (blood sugar levels)Press ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208471,https://www.fda.gov/news-events/press-announcements/fda-approves-adlyxin-treat-type-2-diabetes,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-adlyxin
2016,17,Exondys 51,eteplirsen,2016-09-19,To treat patients with Duchenne muscular dystrophyPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206488,https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-drug-duchenne-muscular-dystrophy,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-exondys-51
2016,18,Lartruvo,olaratumab,2016-10-19,To treat adults with certain types of soft tissue sarcomaPress Release Drug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761038,https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-treatment-advanced-soft-tissue-sarcoma,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-lartruvo
2016,19,Zinplava,bezlotoxumab,2016-10-21,To reduce the recurrence of Clostridium difficile infection in patients aged 18 years or olderDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761046,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-zinplava
2016,20,Eucrisa,crisaborole,2016-12-14,To treat mild to moderate eczema (atopic dermatitis) in patients two years of age and olderPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207695,https://www.fda.gov/news-events/press-announcements/fda-approves-eucrisa-eczema,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-eucrisa
2016,21,Rubraca,rucaparib,2016-12-19,To treat women with a certain type of ovarian cancerPress Release Drug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209115,https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-treatment-advanced-ovarian-cancer,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-rubraca
2016,22,Spinraza,nusinersen,2016-12-23,To treat children and adults with spinal muscular atrophy (SMA)Press ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209531,https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-spinal-muscular-atrophy,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-spinraza
2017,1,Trulance,plecanatide,2017-01-19,To treat Chronic Idiopathic Constipation (CIC) in adult patients.Press ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208745,https://www.fda.gov/news-events/press-announcements/fda-approves-trulance-chronic-idiopathic-constipation,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-trulance
2017,2,Parsabiv,etelcalcetide,2017-02-07,To treat secondary hyperparathyroidism in adult patients with chronic kidney disease undergoing dialysisDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208325,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-parsabiv
2017,3,Emflaza,deflazacort,2017-02-09,To treat patients age 5 years and older with Duchenne muscular dystrophy (DMD)Press ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208684,https://www.fda.gov/news-events/press-announcements/fda-approves-drug-treat-duchenne-muscular-dystrophy,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-emflaza
2017,4,Siliq,brodalumab,2017-02-15,To treat adults with moderate-to-severe plaque psoriasisPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761032,https://www.fda.gov/news-events/press-announcements/fda-approves-new-psoriasis-drug,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-siliq
2017,5,Xermelo,telotristat ethyl,2017-02-28,To treat carcinoid syndrome diarrheaPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208794,https://www.fda.gov/news-events/press-announcements/fda-approves-xermelo-carcinoid-syndrome-diarrhea,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-xermelo
2017,6,Kisqali,ribociclib,2017-03-13,To treat postmenopausal women with a type of advanced breast cancerDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209092,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-kisqali
2017,7,Xadago,safinamide,2017-03-21,To treat Parkinson’s diseasePress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207145,https://www.fda.gov/news-events/press-announcements/fda-approves-drug-treat-parkinsons-disease,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-xadago
2017,8,Bavencio,avelumab,2017-03-23,To treat metastatic Merkel cell carcinomaPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761049,https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-rare-form-skin-cancer,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-bavencio
2017,9,Symproic,naldemedine,2017-03-23,For the treatment of opioid-induced constipationDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208854,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-symproic
2017,10,Zejula,niraparib,2017-03-27,"For the maintenance treatment for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancersPress ReleaseDrug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208447,https://www.fda.gov/news-events/press-announcements/fda-approves-maintenance-treatment-recurrent-epithelial-ovarian-fallopian-tube-or-primary-peritoneal,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-zejula
2017,11,Dupixent,dupilumab,2017-03-28,To treat adults with moderate-to-severe eczema (atopic dermatitis)Press ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761055,https://www.fda.gov/news-events/press-announcements/fda-approves-new-eczema-drug-dupixent,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-dupixent
2017,12,Ocrevus,ocrelizumab,2017-03-28,To treat patients with relapsing and primary progressive forms of multiple sclerosisPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761053,https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treat-multiple-sclerosis,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-ocrevus
2017,13,Austedo,deutetrabenazine,2017-04-03,For the treatment of chorea associated with Huntington’s disease Drug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208082,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-austedo
2017,14,Ingrezza,valbenazine,2017-04-11,To treat adults with tardive dyskinesia Press Release  Drug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209241,https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-tardive-dyskinesia,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-ingrezza
2017,15,Brineura,cerliponase alfa,2017-04-27,To treat a specific form of Batten diseasePress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761052,https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-form-batten-disease,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-brineura
2017,16,Alunbrig,brigatinib,2017-04-28,To treat patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinibDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208772,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-alunbrig
2017,17,Rydapt,midostaurin,2017-04-28,"To treat acute myeloid leukemia, advanced systemic mastocytosisPress ReleaseDrug Trials Snapshot for advanced systemic mastocytosisDrug Trials Snapshot for acute Myeloid leukemia",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207997,https://www.fda.gov/news-events/press-announcements/fda-approves-new-combination-treatment-acute-myeloid-leukemia,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-rydapt
2017,18,Tymlos,abaloparatide,2017-04-28,To treat osteoporosis in postmenopausal women at high risk of fracture or those who have failed other therapiesDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208743,,
2017,19,Imfinzi,durvalumab,2017-05-01,To treat patients with locally advanced or metastatic urothelial carcinomaWeb PostDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761069,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-imfinzi
2017,20,Radicava,edaravone,2017-05-05,To treat patients with amyotrophic lateral sclerosis (ALS)Press ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209176,https://www.fda.gov/news-events/press-announcements/fda-approves-drug-treat-als,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-radicava
2017,21,Kevzara,sarilumab,2017-05-22,To treat adult rheumatoid arthritisDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761037,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-kevzara
2017,22,Baxdela,delafloxacin,2017-06-19,To treat patients with acute bacterial skin infectionsDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208610,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-baxdela
2017,23,Bevyxxa,betrixaban,2017-06-23,For the prophylaxis of venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illnessDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208383,,
2017,24,Tremfya,guselkumab,2017-07-13,For the treatment of adult patients with moderate-to-severe plaque psoriasisDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761061,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-tremfya
2017,25,Nerlynx,neratinib maleate,2017-07-17,To reduce the risk of breast cancer returningPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208051,https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-reduce-risk-breast-cancer-returning,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-nerlynx
2017,26,Vosevi,"sofosbuvir, velpatasvir and voxilaprevir",2017-07-18,To treat adults with chronic hepatitis C virusPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209195,https://www.fda.gov/news-events/press-announcements/fda-approves-vosevi-hepatitis-c,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-vosevi
2017,27,Idhifa,enasidenib,2017-08-01,To treat relapsed or refractory acute myeloid leukemiaPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209606,https://www.fda.gov/news-events/press-announcements/fda-approves-new-targeted-treatment-relapsed-or-refractory-acute-myeloid-leukemia,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-idhifa
2017,28,Mavyret,glecaprevir and pibrentasvir,2017-08-03,To treat adults with chronic hepatitis C virusPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209394,https://www.fda.gov/news-events/press-announcements/fda-approves-mavyret-hepatitis-c,https://www.fda.gov/drugs/drug-approvals-and-databases/mavyret-drug-trials-snapshot
2017,29,Besponsa,inotuzumab ozogamicin,2017-08-17,To treat adults with relapsed or refractory acute lymphoblastic leukemiaPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761040,https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-adults-relapsed-or-refractory-acute-lymphoblastic-leukemia,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-besponsa
2017,30,Vabomere,meropenem and vaborbactam,2017-08-29,To treat adults with complicated urinary tract infectionsPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209776,https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibacterial-drug,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-vabomere
2017,31,benznidazole,benznidazole,2017-08-29,To treat children ages 2 to 12 years old with Chagas diseasePress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209570,https://www.fda.gov/news-events/press-announcements/fda-approves-first-us-treatment-chagas-disease,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-benznidazole
2017,32,Aliqopa,copanlisib,2017-09-14,To treat adults with relapsed follicular lymphomaPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209936,https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-adults-relapsed-follicular-lymphoma,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-aliqopa
2017,33,Solosec,secnidazole,2017-09-15,To treat bacterial vaginosisDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209363,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-solosec
2017,34,Verzenio,abemaciclib,2017-09-28,To treat certain advanced or metastatic breast cancersPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208716,https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-certain-advanced-or-metastatic-breast-cancers,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-verzenio
2017,35,Calquence,acalabrutinib,2017-10-31,To treat adults with mantle cell lymphomaPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210259,https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-adults-mantle-cell-lymphoma,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-calquence
2017,36,Vyzulta,latanoprostene bunod ophthalmic solution,2017-11-02,To treat intraocular pressure in patients with open-angle glaucoma or ocular hypertension.Drug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207795,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-vyzulta
2017,37,Prevymis,letermovir,2017-11-08,To prevent infection after bone marrow transplantDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209939,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-prevymis
2017,38,Fasenra,benralizumab,2017-11-14,"For add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761070,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-fasenra
2017,39,Mepsevii,vestronidase alfa-vjbk,2017-11-15,"To treat pediatric and adult patients with an inherited metabolic condition called mucopolysaccharidosis type VII (MPS VII), also known as Sly syndrome.Press ReleaseDrug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761047,https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-rare-genetic-enzyme-disorder,
2017,40,Hemlibra,emicizumab,2017-11-16,To prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A who have developed antibodies called Factor VIII (FVIII) inhibitors.Press ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761083,https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-prevent-bleeding-certain-patients-hemophilia,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-hemlibra
2017,41,Ozempic,semaglutide,2017-12-05,To improve glycemic control in adults with type 2 diabetes mellitusDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209637,,
2017,42,Xepi,ozenoxacin,2017-12-11,To treat impetigoDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208945,,
2017,43,Rhopressa,netarsudil,2017-12-18,To treat glaucoma or ocular hypertensionDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208254,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-rhopressa
2017,44,Steglatro,ertugliflozin,2017-12-19,To improve glycemic control in adults with type 2 diabetes mellitusDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209803,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-steglatro
2017,45,Macrilen,macimorelin acetate,2017-12-20,For the diagnosis of adult growth hormone deficiencyDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205598,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-marcrilen
2017,46,Giapreza,angiotensin II,2017-12-21,To increase blood pressure in adults with septic or other distributive shockPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209360,https://www.fda.gov/news-events/press-announcements/fda-approves-drug-treat-dangerously-low-blood-pressure,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-giapreza
2018,1,Lutathera,lutetium Lu 177 dotatate,2018-01-26,To treat a type of cancer that affects the pancreas or gastrointestinal tract called gastroenteropancreatic neuroendocrine tumors (GEP-NETs).Press ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208700,https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-certain-digestive-tract-cancers,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-lutathera
2018,2,Biktarvy,"bictegravir, embitcitabine, tenofovir alafenamide",2018-02-07,To treat infection in adults who have no antiretroviral treatment history or to replace the current antiretroviral regimenDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210251,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-biktarvy
2018,3,Symdeko,tezacaftor; ivacaftor,2018-02-12,To treat cystic fibrosis in patients age 12 years and olderDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210491,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-symdeko
2018,4,Erleada,apalutamide,2018-02-14,To treat a certain type of prostate cancer using novel clinical trial endpointPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210951,https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-certain-type-prostate-cancer-using-novel-clinical-trial-endpoint,
2018,5,Trogarzo,ibalizumab-uiyk,2018-03-06,To treat HIV patients who have limited treatment optionsPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761065,https://www.fda.gov/news-events/press-announcements/fda-approves-new-hiv-treatment-patients-who-have-limited-treatment-options,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-trogarzo
2018,6,Ilumya,tildrakizumab,2018-03-20,To treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapyDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761067,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-ilumya
2018,7,Tavalisse,fostamatinib,2018-04-17,To treat thrombocytopenia in adult patients with persistent or chronic immune thrombocytopenia (ITP)Drug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209299,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-tavalisse
2018,8,Crysvita,burosumab-twza,2018-04-17,"To treat adults and children ages 1 year and older with x-linked hypophosphatemia (XLH), a rare, inherited form of ricketsPress ReleaseDrug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761068,https://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-rare-inherited-form-rickets-x-linked-hypophosphatemia,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-crysvita
2018,9,Akynzeo,fosnetupitant and palonosetron,2018-04-19,To prevent acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapyDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210493,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-akynzeo
2018,10,Lucemyra,lofexidine hydrochloride,2018-05-16,For the non-opioid treatment for management of opioid withdrawal symptoms in adultsPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209229,https://www.fda.gov/news-events/press-announcements/fda-approves-first-non-opioid-treatment-management-opioid-withdrawal-symptoms-adults,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-lucemyra
2018,11,Aimovig,erenumab-aooe,2018-05-17,For the preventive treatment for migrainePress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761077,https://www.fda.gov/news-events/press-announcements/fda-approves-novel-preventive-treatment-migraine,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-aimovig
2018,12,Lokelma,sodium zirconium cyclosilicate,2018-05-18,To treat hyperkalemiaDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207078,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-lokelma
2018,13,Doptelet,avatrombopag,2018-05-21,To treat low blood platelet count (thrombocytopenia) in adults with chronic liver disease who are scheduled to undergo a medical or dental procedurePress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210238,https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-patients-chronic-liver-disease-who-have-low-blood-platelets-and-are-undergoing,
2018,14,Palynziq,pegvaliase-pqpz,2018-05-24,To treat adults with a rare and serious genetic disease known as phenylketonuria (PKU)Press ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761079,https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-pku-rare-and-serious-genetic-disease,
2018,15,Olumiant,baricitinib,2018-05-31,To treat moderately to severely active rheumatoid arthritisDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=207924,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-olumiant
2018,16,Moxidectin,moxidectin,2018-06-13,To treat onchocerciasis due to Onchocerca volvulus in patients aged 12 years and olderDrug Trials Snapshot,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=210867,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-moxidectin
2018,17,Epidioloex,cannabidiol,2018-06-25,"To treat rare, severe forms of epilepsyPress ReleaseDrug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210365,https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-severe-forms,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-epidiolex
2018,18,Zemdri,plazomicin,2018-06-25,To treat adults with complicated urinary tract infectionsDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210303,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-zemdri
2018,19,Mektovi,binimetinib,2018-06-27,To treat unresectable or metastatic melanomaDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210498,,
2018,20,Braftovi,encorafenib,2018-06-27,To treat unresectable or metastatic melanomaDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210496,,
2018,21,TPOXX,tecovirimat,2018-07-13,To treat smallpoxPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208627,https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-indication-treatment-smallpox,
2018,22,Tibsovo,ivosidenib,2018-07-20,To treat patients with relapsed or refractory acute myeloid leukemiaPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211192,https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-treatment-patients-relapsed-or-refractory-acute-myeloid-leukemia-who,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-tibsovo
2018,23,Krintafel,tafenoquine,2018-07-20,For the radical cure (prevention of relapse) of Plasmodium vivax malariaDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210795,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-krintafel
2018,24,Orilissa,elagolix sodium,2018-07-23,For the management of moderate to severe pain associated with endometriosisDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210450,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-orilissa
2018,25,Omegaven,fish oil triglycerides,2018-07-27,As a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasisDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210589,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-omegaven
2018,26,Mulpleta,lusutrombopag,2018-07-31,To treat thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedureDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210923,,
2018,27,Poteligeo,mogamulizumab-kpkc,2018-08-08,To treat two rare types of non-Hodgkin lymphomaPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761051,https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-two-rare-types-non-hodgkin-lymphoma,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-poteligeo
2018,28,Onpattro,patisiran,2018-08-10,To treat the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adult patientsPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210922,https://www.fda.gov/news-events/press-announcements/fda-approves-first-its-kind-targeted-rna-based-therapy-treat-rare-disease,
2018,29,Annovera,segesterone acetate and ethinyl estradiol vaginal system,2018-08-10,New vaginal ring used to prevent pregnancy for an entire yearPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209627,https://www.fda.gov/news-events/press-announcements/fda-approves-new-vaginal-ring-one-year-birth-control,
2018,30,Galafold,migalastat,2018-08-10,To treat treat adults with Fabry disease.Press ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208623,https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-rare-genetic-disorder-fabry-disease,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-galafold
2018,31,Diacomit,stiripentol,2018-08-20,To treat seizures associated with Dravet syndrome in patients 2 years of age and older taking clobazamDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=206709,,
2018,32,Oxervate,cenegermin-bkbj,2018-08-22,To treat neurotrophic keratitisPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761094,https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-neurotrophic-keratitis-rare-eye-disease,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-oxervate
2018,33,Takhzyro,lanadelumab,2018-08-23,To treat types I and II hereditary angioedemaDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761090,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-takhzyro
2018,34,Xerava,eravacycline,2018-08-27,To treat complicated intra-abdominal infections in patients 18 years of age and olderDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211109,,
2018,35,Pifeltro,doravirine,2018-08-30,To treat HIV-1 infection in adult patientsDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210806,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-pifeltro
2018,36,Lumoxiti,moxetumomab pasudotox-tdfk,2018-09-13,To treat hairy cell leukemiaPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761104,https://www.fda.gov/news-events/press-announcements/fda-approves-new-kind-treatment-hairy-cell-leukemia,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-lumoxiti
2018,37,Ajovy,fremanezumab-vfrm,2018-09-14,For the preventive treatment of migraine in adultsDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761089,,https://www.fda.gov/drugs/drug-trials-snapshot-ajovy
2018,38,Copiktra,duvelisib,2018-09-24,"To treat relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and follicular lymphomaDrug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211155,,https://www.fda.gov/drugs/drug-trials-snapshots-copiktra
2018,39,Emgality,galcanezumab-gnlm,2018-09-27,For the preventive treatment of migraine in adultsDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761063,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-emgality
2018,40,Vizimpro,dacomitinib,2018-09-27,To treat metastatic non-small-cell lung cancerDrug Trials Snapshot,httphttp://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211288,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-vizimpro
2018,41,Libtayo,cemiplimab-rwlc,2018-09-28,To treat cutaneous squamous cell carcinoma (CSCC)Drug Trial Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761097,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-libtayo
2018,42,Seysara,sarecycline,2018-10-01,To treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and olderDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209521,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-seysara
2018,43,Nuzyra,omadacycline,2018-10-02,To treat community-acquired bacterial pneumonia and acute bacterial skin and skin structure infectionsDrug Trials Snapshot for community-acquired bacterial pneumonia,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209816,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-nuzyra
2018,44,Revcovi,elapegademase-lvlr,2018-10-05,To treat Adenosine Deaminase-Severe Combined Immunodeficiency (ADA-SCID)Drug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761092,,
2018,45,Tegsedi,inotersen,2018-10-05,To treat polyneuropathy of hereditary transthyretin-mediated amyloidosis in adultsDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211172,,
2018,46,Talzenna,talazoparib,2018-10-16,To treat locally advanced or metastatic breast cancer patients with a germline BRCA mutation.Drug Trials Snapshot,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211651,,
2018,47,Xofluza,baloxavir marboxil,2018-10-24,To treat acute uncomplicated influenza in patients who have been symptomatic for no more than 48 hours.Press ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210854,https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treat-influenza,
2018,48,Lorbrena,lorlatinib,2018-11-02,To treat patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancerDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210868,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-lorbrena
2018,49,Yupelri,revefenacin,2018-11-09,To treat patients with chronic obstructive pulmonary disease (COPD)Drug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210598,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-yupelri
2018,50,Aemcolo,rifamycin,2018-11-16,To treat travelers’ diarrheaPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210910,https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treat-travelers-diarrhea,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-aemcolo
2018,51,Gamifant,emapalumab-lzsgemapalumab-lzsg,2018-11-20,To treat primary hemophagocytic lymphohistiocytosis (HLH)Press ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761107,https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-specifically-patients-rare-and-life-threatening-type-immune-disease,
2018,52,Daurismo,glasdegib,2018-11-21,To treat newly-diagnosed acute myeloid leukemia (AML) in adult patientsPress Release Drug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210656,https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-patients-acute-myeloid-leukemia,
2018,53,Vitrakvi,larotrectinib,2018-11-26,To treat patients whose cancers have a specific genetic feature (biomarker)Press ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210861,https://www.fda.gov/news-events/press-announcements/fda-approves-oncology-drug-targets-key-genetic-driver-cancer-rather-specific-type-tumor,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-vitrakvi
2018,54,Firdapse,amifampridine,2018-11-28,To treat  Lambert-Eaton myasthenic syndrome (LEMS) in adultsPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208078,https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-lambert-eaton-myasthenic-syndrome-rare-autoimmune-disorder,
2018,55,Xospata,gilteritinib,2018-11-28,To treat patients who have relapsed or refractory acute myeloid leukemia (AML)Press ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211349,https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-adult-patients-who-have-relapsed-or-refractory-acute-myeloid-leukemia-aml,
2018,56,Motegrity,prucalopride,2018-12-14,To treat chronic idiopathic constipationDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210166,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-motegrity
2018,57,Asparlas,calaspargase pegol-mknl,2018-12-20,To treat acute lymphoblastic leukemia (ALL) in pediatric and young adult patients age 1 month to 21 yearsDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761102,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-asparlas
2018,58,Elzonris,tagraxofusp-erzs,2018-12-21,To treat blastic plasmacytoid dendritic cell neoplasm (BPDCN)Press ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761116,https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-rare-blood-disease,
2018,59,Ultomiris,ravulizumab,2018-12-21,"To treat paroxysmal nocturnal hemoglobinuria (PNH)
			Press ReleaseDrug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761108,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-ultomiris
2019,1,Jeuveau,prabotulinumtoxinA-xvfs,2019-02-01,For the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761085,,
2019,2,Cablivi,caplacizumab-yhdp,2019-02-06,To treat adult patients with acquired thrombotic thrombocytopenic purpura (aTTP)Press ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761112,https://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-treatment-adult-patients-rare-blood-clotting-disorder,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-jeuveau
2019,3,Egaten,triclabendazole,2019-02-13,"To treat fascioliasis, a parasitic infestation caused by two species of flatworms or trematodes that mainly the affect the liver, sometimes referred to as “liver flukes”Drug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=208711,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-egaten
2019,4,Zulresso,brexanolone,2019-03-19,To treat postpartum depression (PPD) in adult womenPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211371,https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-post-partum-depression,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-zulresso
2019,5,Sunosi,solriamfetol,2019-03-20,To treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apneaDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211230,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-sunosi
2019,6,Mayzent,siponimod,2019-03-26,To treat adults with relapsing forms of multiple sclerosisPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209884,https://www.fda.gov/news-events/press-announcements/fda-approves-new-oral-drug-treat-multiple-sclerosis,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-mayzent
2019,7,Evenity,romosozumab-aqqg,2019-04-09,To treat osteoporosis in postmenopausal women at high risk of fracturePress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761062,https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-osteoporosis-postmenopausal-women-high-risk-fracture,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-evenity
2019,8,Balversa,erdafitinib,2019-04-12,To treat adult patients with locally advanced or metastatic bladder cancerPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212018,https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-metastatic-bladder-cancer,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-balversa
2019,9,Skyrizi,risankizumab-rzaa,2019-04-23,To treat moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapyDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761105,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-skyrizi
2019,10,Vyndaqel,tafamidis meglumine,2019-05-03,To treat heart disease (cardiomyopathy) caused by transthyretin mediated amyloidosis (ATTR-CM) in adultsPress Release Drug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211996,https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatments-heart-disease-caused-serious-rare-disease-transthyretin-mediated,
2019,11,Piqray,alpelisib,2019-05-24,To treat breast cancerPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212526,https://www.fda.gov/news-events/press-announcements/fda-approves-first-pi3k-inhibitor-breast-cancer,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-piqray
2019,12,Polivy,polatuzumab vedotin-piiq,2019-06-10,To treat adult patients with relapsed or refractory diffuse large B-cell lymphomaPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761121,https://www.fda.gov/news-events/press-announcements/fda-approves-first-chemoimmunotherapy-regimen-patients-relapsed-or-refractory-diffuse-large-b-cell,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-polivy
2019,13,Vyleesi,bremelanotide,2018-06-21,To treat hypoactive sexual desire disorder in premenopausal women.Press ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210557,https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-hypoactive-sexual-desire-disorder-premenopausal-women,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-vyleesi
2019,14,Xpovio,selinexor,2019-07-03,To treat adult patients with relapsed or refractory multiple myeloma (RRMM)Press ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212306,https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-refractory-multiple-myeloma,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-xpovio
2019,15,Recarbrio,"imipenem, cilastatin and relebactam",2019-07-16,To treat complicated urinary tract and complicated intra-abdominal infectionsPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212819,https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-complicated-urinary-tract-and-complicated-intra-abdominal-infections,
2019,16,Accrufer,ferric maltol,2019-07-25,To treat iron deficiency anemia in adultsDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212320,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-accrufer
2019,17,Nubeqa,darolutamide,2019-07-30,To treat adult patients with non-metastatic castration resistant prostate cancerDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212099,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-nubeqa
2019,18,Turalio,pexidartinib,2019-08-02,To treat adult patients with symptomatic tenosynovial giant cell tumorPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211810,https://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-rare-joint-tumor,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-turalio
2019,20,Wakix,pitolisant,2019-08-14,To treat excessive daytime sleepiness (EDS) in adult patients with narcolepsyDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021115,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-wakix
2019,21,Rozlytrek,entrectinib,2019-08-15,"To treat adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive
			To treat adult and pediatric patients 12 years of age and older with solid tumorsPress ReleaseDrug Trials Snapshot: Pediatric patients 12 years of age and older with solid tumorsDrug Trials Snapshot: Metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212725,https://www.fda.gov/news-events/press-announcements/fda-approves-third-oncology-drug-targets-key-genetic-driver-cancer-rather-specific-type-tumor,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-rozlytrek-0
2019,22,Inrebic,fedratinib,2019-08-16,To treat adult patients with intermediate-2 or high-risk primary or secondary myelofibrosisPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212327,https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-patients-rare-bone-marrow-disorder,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-inrebic
2019,23,Rinvoq,upadacitinib,2019-08-16,To treat adults with moderately to severely active rheumatoid arthritisDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211675,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-rinvoq
2019,24,Xenleta,lefamulin,2019-08-19,To treat adults with community-acquired bacterial pneumoniaPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211672,https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibiotic-treat-community-acquired-bacterial-pneumonia,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-xenleta
2019,25,Ga-68-DOTATOC,Ga-68-DOTATOC,2019-08-21,For use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs)Drug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210828,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-ga-68-dotatoc
2019,26,Nourianz,istradefylline,2019-08-27,To treat adult patients with Parkinson’s disease experiencing “off” episodesPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=022075,https://www.fda.gov/news-events/press-announcements/fda-approves-new-add-drug-treat-episodes-adults-parkinsons-disease,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-nourianz
2019,27,Ibsrela,tenapanor,2019-09-12,To treat irritable bowel syndrome with constipation in adults.Drug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211801,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-ibsrela
2019,28,Aklief,trifarotene,2019-10-04,For the topical treatment of acne vulgaris in patients 9 years of age and olderDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211527,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-aklief
2019,29,Beovu,brolucizumab–dbll,2019-10-07,Treatment of wet age-related macular degenerationDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761125,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-beovu
2019,30,Scenesse,afamelanotide,2019-10-08,To increase pain-free light exposure in adult patients with a history of phototoxic reactions (damage to skin) from erythropoietic protoporphyriaPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210797,https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-increase-pain-free-light-exposure-patients-rare-disorder,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-scenesse
2019,32,Reyvow,lasmiditan,2019-10-11,"For the acute treatment of migraine with or without aura, in adultsPress ReleaseDrug Trials Snapshots",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211280,https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-patients-migraine,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-reyvow
2019,33,Trikafta,elexacaftor/ivacaftor/tezacaftor,2019-10-21,To treat patients 12 years of age and older with the most common gene mutation that causes cystic fibrosisPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212273,https://www.fda.gov/news-events/press-announcements/fda-approves-new-breakthrough-therapy-cystic-fibrosis,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-trikafta
2019,34,ExEm Foam,air polymer-type A,2019-11-07,A diagnostic agent used to assess fallopian tube patency (openness) in women with known or suspected infertilityDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212279,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-exem-foam
2019,35,Reblozyl,luspatercept–aamt,2019-11-08,For the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell transfusionsPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761136,https://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-treat-patients-rare-blood-disorder,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-reblozyl
2019,36,Brukinsa,zanubrutinib,2019-11-14,"To treat certain patients with mantle cell lymphoma, a form of blood cancerPress ReleaseDrug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213217,https://www.fda.gov/news-events/press-announcements/fda-approves-therapy-treat-patients-relapsed-and-refractory-mantle-cell-lymphoma-supported-clinical,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-brukinsa
2019,37,Fetroja,cefiderocol,2019-11-14,To treat patients with complicated urinary tract infections who have limited or no alternative treatment optionsPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209445,https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibacterial-drug-treat-complicated-urinary-tract-infections-part-ongoing-efforts,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-fetroja
2019,38,Adakveo,crizanlizumab-tmca,2019-11-15,To treat patients with painful complication of sickle cell diseasePress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761128,https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-treat-patients-painful-complication-sickle-cell-disease,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-adakveo
2019,39,Givlaari,givosiran,2019-11-20,"To treat acute hepatic porphyria, a rare blood disorderPress ReleaseDrug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212194,https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-inherited-rare-disease,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-givlaari
2019,40,Xcopri,cenobamate,2019-11-21,To treat partial onset seizuresPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212839,https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-adults-partial-onset-seizures,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-xcopri
2019,41,Oxbryta,voxelotor,2019-11-25,To treat sickle cell diseasePress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213137,https://www.fda.gov/news-events/press-announcements/fda-approves-novel-treatment-target-abnormality-sickle-cell-disease,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-oxbryta
2019,42,Vyondys 53,golodirsen,2019-12-12,To treat certain patients with Duchenne muscular dystrophyPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211970,https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-vyondys-53
2019,43,Padcev,enfortumab vedotin-ejfv,2019-12-18,To treat refractory bladder cancerPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761137,https://www.fda.gov/news-events/press-announcements/fda-approves-new-type-therapy-treat-advanced-urothelial-cancer,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-padcev
2019,44,TissueBlue,Brilliant Blue G Ophthalmic Solution,2019-12-20,Dye used in eye surgeryDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209569,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-tissueblue
2019,45,Caplyta,lumateperone tosylate,2019-12-20,To treat schizophreniaDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209500,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-caplyta
2019,46,Dayvigo,lemborexant,2019-12-20,To treat insomniaDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212028,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-dayvigo
2019,47,Enhertu,fam-trastuzumab deruxtecan-nxki,2019-12-20,To treat metastatic breast cancerPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761139,https://www.fda.govhttps://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-option-patients-her2-positive-breast-cancer-who-have-progressed-available,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-enhertu
2019,48,Ubrelvy,ubrogepant,2019-12-23,to treat acute treatment of migraine with or without aura in adultsPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211765,https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-adults-migraine,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-ubrelvy
2020,1,Ayvakit,avapritinib,2020-01-09,To treat adults with unresectable or metastatic gastrointestinal stromal tumor (GIST)FDA InformationDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212608,,
2020,2,Tepezza,teprotumumab-trbw,2020-01-21,To treat Thyroid eye diseasePress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761143,https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-thyroid-eye-disease,
2020,3,Tazverik,tazemetostat,2020-01-23,To treat epithelioid sarcomaPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211723,https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-option-specifically-patients-epithelioid-sarcoma-rare-soft-tissue,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-tazverik
2020,4,Pizensy,lactitol,2020-02-12,To treat chronic idiopathic constipation (CIC) in adultsDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211281,,
2020,5,Nexletol,bempedoic acid,2020-02-21,To treat adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-CDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211616,,https://www.fda.gov/drugs/resources-information-approved-drugs/drug-trials-snapshots-nexletol
2020,6,Vyepti,eptinezumab-jjmr,2020-02-21,For the preventive treatment of migraine in adultsDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761119,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-vyepti
2020,7,Barhemsys,amisulpride,2020-02-26,To help prevent nausea and vomiting after surgeryDrug Trial Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209510,,https://www.fda.gov/drugs/development-approval-process-drugs/drug-trials-snapshots-barhemsys
2020,8,Nurtec ODT,rimegepant,2020-02-27,To treat migraineDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212728,,https://www.fda.gov/drugs/development-approval-process-drugs/drug-trials-snapshots-nurtec-odt
2020,9,Sarclisa,isatuximab,2020-03-02,To treat multiple mylomaPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761113,https://www.fda.gov/news-events/press-announcements/fda-approves-new-therapy-patients-previously-treated-multiple-myeloma,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-sarclisa
2020,10,Isturisa,osilodrostat,2020-03-06,To treat adults with Cushing’s disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the diseasePress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212801,https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-adults-cushings-disease,
2020,11,Zeposia,ozanimod,2020-03-25,To treat relapsing forms of multiple sclerosisDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=209899,,https://www.fda.gov/drugs/development-approval-process-drugs/drug-trials-snapshots-zeposia
2020,12,Koselugo,selumetinib,2020-04-10,"To treat neurofibromatosis type 1, a genetic disorder of the nervous system causing tumors to grow on nervesDrug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213756,,https://www.fda.gov/drugs/resources-information-approved-drugs/drug-trials-snapshots-koselugo
2020,13,Tukysa,tucatinib,2020-04-17,To treat advanced unresectable or metastatic HER2-positive breast cancerDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213411,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-tukysa
2020,14,Pemazyre,pemigatinib,2020-04-17,"To treat certain patients with cholangiocarcinoma, a rare form of cancer that forms in bile ductsPress ReleaseDrug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213736,https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-treatment-patients-cholangiocarcinoma-cancer-bile-ducts,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-pemazyre
2020,15,Trodelvy,sacituzumab govitecan-hziy,2020-04-22,To treat adult patients with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic diseasePress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761115,,
2020,16,Ongentys,opicapone,2020-04-24,To treat patients with Parkinson’s disease experiencing “off” episodesDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212489,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-ongentys
2020,17,Tabrecta,capmatinib,2020-05-06,To treat patients with non small cell lung cancerPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213591,https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-treat-aggressive-form-lung-cancer,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-tabrecta
2020,18,Retevmo,selpercatinib,2020-05-08,To treat lung and thyroid cancersPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213246,https://www.fda.gov/news-events/press-announcements/fda-approves-first-therapy-patients-lung-and-thyroid-cancers-certain-genetic-mutation-or-fusion,https://www.fda.gov/drugs/development-approval-process-drugs/drug-trials-snapshots-retevmo
2020,19,Qinlock,ripretinib,2020-05-15,To treat advanced gastrointestinal-stromal tumorsPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213973,https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-fourth-line-treatment-advanced-gastrointestinal-stromal-tumors,
2020,20,Cerianna,fluoroestradiol F18,2020-05-20,Diagnostic imaging agent for certain patients with breast cancerDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212155,,
2020,21,Artesunate,artesunate,2020-05-26,To treat severe malariaPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213036,https://www.fda.gov/news-events/press-announcements/fda-approves-only-drug-us-treat-severe-malaria,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-artesunate
2020,22,Tauvid,flortaucipir F18,2020-05-28,Diagnostic agent for patients with Alzheimer’s diseasePress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212123,https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-image-tau-pathology-patients-being-evaluated-alzheimers-disease,
2020,23,Uplizna,inebilizumab-cdon,2020-06-11,To treat neuromyelitis optica spectrum disorderPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761142,https://www.fda.gov/news-events/press-announcements/fda-approves-new-therapy-rare-disease-affecting-optic-nerve-spinal-cord,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-uplizna
2020,24,Zepzelca,lurbinectedin,2020-06-15,To treat metastatic small cell lung cancerDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213702,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-zepzelca
2020,25,Dojolvi,triheptanoin,2020-06-30,To treat molecularly long-chain fatty acid oxidation disordersDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213687,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-dojolvi
2020,26,Byfavo,remimazolam,2020-07-02,For sedationDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212295,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-byfavo
2020,27,Rukobia,fostemsavir,2020-07-02,To treat HIVPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212950,https://www.fda.gov/news-events/press-announcements/fda-approves-new-hiv-treatment-patients-limited-treatment-options,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-rukobia
2020,28,Inqovi,decitabine and cedazuridine,2020-07-07,To treat adult patients with myelodysplastic syndromesDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212576,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-inqovi
2020,29,Xeglyze,abametapir,2020-07-24,To treat head liceDrug Trials Snapshot,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206966,,
2020,30,Monjuvi,tafasitamab-cxix,2020-07-31,To treat relapsed or refractory diffuse large B-cell lymphomaDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761163,,
2020,31,Blenrep,belantamab mafodotin-blmf,2020-08-05,To treat multiple myelomaDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761158,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-blenrep
2020,32,Lampit,nifurtimox,2020-08-06,To treat Chagas disease in certain pediatric patients younger than age 18Drug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213464,,https://www.fda.gov/drugs/development-approval-process-drugs/drug-trials-snapshots-lampit
2020,33,Evrysdi,risdiplam,2020-08-07,To treat spinal muscular atrophyPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213535,https://www.fda.gov/news-events/press-announcements/fda-approves-oral-treatment-spinal-muscular-atrophy,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-evrysdi
2020,34,Olinvyk,oliceridine,2020-08-07,To manage acute pain in certain adultsPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210730,https://www.fda.gov/news-events/press-announcements/fda-approves-new-opioid-intravenous-use-hospitals-other-controlled-clinical-settings,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-olinvyk
2020,35,Viltepso,viltolarsen,2020-08-12,To treat Duchenne muscular dystrophyPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212154,https://www.fda.gov/news-events/press-announcements/fda-approves-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-viltepso
2020,36,Enspryng,satralizumab-mwge,2020-08-14,To treat neuromyelitis optica spectrum disorderPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761149,https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-rare-disease-affecting-optic-nerves-spinal-cord,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-enspryng
2020,37,Winlevi,clascoterone,2020-08-26,To treat acneDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213433,,
2020,38,Sogroya,somapacitan-beco,2020-08-28,Growth hormoneDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761156,,
2020,39,Detectnet,copper Cu 64 dotatate injection,2020-09-03,To help detect certain types of neuroendocrine tumorsDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213227,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-detectnet
2020,40,Gavreto,pralsetinib,2020-09-04,To treat non-small lung cancerDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213721,,
2020,41,Inmazeb,"atoltivimab, maftivimab, and odesivimab-ebgn",2020-10-14,To treat ebola virusPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761169,https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-ebola-virus,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-inmazeb
2020,42,Veklury,remdesivir,2020-10-22,To treat COVID-19Press ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214787,https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-veklury
2020,43,Zokinvy,lonafarnib,2020-11-20,To treat rare conditions related to premature agingPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213969,https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-hutchinson-gilford-progeria-syndrome-and-some-progeroid-laminopathies,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-zokinvy
2020,44,Oxlumo,lumasiran,2020-11-23,To treat hyperoxaluria type 1Press ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214103,https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-rare-metabolic-disorder,
2020,45,Imcivree,setmelanotide,2020-11-25,"To treat obesity and the control of hunger associated with pro-opiomelanocortin deficiency, a rare disorder that causes severe obesity that begins at an early ageDrug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213793,,https://www.fda.gov/drugs/drug-trials-snapshots-imcivree
2020,46,Danyelza,naxitamab-gqgk,2020-11-25,To treat high-risk refractory or relapsed neuroblastomaDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761171,,
2020,47,Gallium 68 PSMA-11,Gallium 68 PSMA-11,2020-12-01,For detection and localization of prostate cancerPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212642,https://www.fda.gov/news-events/press-announcements/fda-approves-first-psma-targeted-pet-imaging-drug-men-prostate-cancer,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-ga-68-psma-11
2020,48,Orladeyo,berotralstat,2020-12-03,To treat patients with hereditary angioedemaDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214094,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-orladeyo
2020,49,Klisyri,tirbanibulin,2020-12-14,To treat actinic Keratosis of the face or scalpDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213189,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-klisyri
2020,50,Margenza,margetuximab (anti-HER2 mAb,2020-12-16,To treat HER2+ breast cancerDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761150,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-margenza
2020,51,Orgovyx,relugolix,2020-12-18,To treat advanced prostate cancerPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214621,https://www.fda.govhttps://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-hormone-therapy-treating-advanced-prostate-cancer,
2020,52,Ebanga,ansuvimab-zykl,2020-12-21,To treat ebolaDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761172,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-ebanga
2020,53,Gemtesa,vibegron,2020-12-23,To treat overactive bladderDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213006,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-gemtesa
2021,1,Verquvo,vericiguat,2021-01-19,To mitigate the risk of cardiovascular death and hospitalization for chronic heart failureDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214377,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-verquvo
2021,2,Cabenuva,cabotegravir and rilpivirine (co-packaged),2021-01-21,To treat HIVPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212888,https://www.fda.gov/news-events/press-announcements/fda-approves-first-extended-release-injectable-drug-regimen-adults-living-hiv,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-cabenuva
2021,3,Lupkynis,voclosporin,2021-01-22,To treat lupus nephritisDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213716,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-lupkynis
2021,4,Tepmetko,tepotinib,2021-02-03,To treat non-small cell lung cancerDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214096,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-tepmetko
2021,5,Ukoniq,umbralisib,2021-02-05,To treat marginal zone lymphoma and follicular lymphomaDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213176,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-ukoniq-0
2021,6,Evkeeza,evinacumab-dgnb,2021-02-11,To treat homozygous familial hypercholesterolemiaDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761181,,
2021,7,Cosela,trilacicilib,2021-02-12,To mitigate chemotherapy-induced myelosuppression in small cell lung cancerPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214200,https://www.fda.gov/news-events/press-announcements/fda-approves-drug-reduce-bone-marrow-suppression-caused-chemotherapy,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-cosela
2021,8,Amondys 45,casimersen,2021-02-25,To treat Duchenne muscular dystrophyPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213026,https://www.fda.gov/news-events/press-announcements/fda-approves-targeted-treatment-rare-duchenne-muscular-dystrophy-mutation-0,
2021,9,Nulibry,fosdenopterin,2021-02-26,To reduce the risk of mortality in molybdenum cofactor deficiency Type APress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214018,https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-molybdenum-cofactor-deficiency-type,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-nulibry
2021,10,Pepaxto,melphalan flufenamide,2021-02-26,To treat relapsed or refractory multiple myelomaDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214383,,
2021,11,Azstarys,"serdexmethylphenidate and
			dexmethylphenidate",2021-03-02,To treat attention deficit hyperactivity disorderDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212994,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-azstarys
2021,12,Fotivda,tivozanib,2021-03-10,To treat renal cell carcinomaDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=212904,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-fotivda
2021,13,Ponvory,ponesimod,2021-03-18,To treat relapsing forms of multiple sclerosisDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213498,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-ponvory
2021,14,Zegalogue,dasiglucagon,2021-03-22,To treat severe hypoglycemiaDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214231,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-zegalogue
2021,15,Qelbree,viloxazine,2021-04-02,To treat attention deficit hyperactivity disorderDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=211964,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-qelbree
2021,16,Nextstellis,drospirenone and estetrol,2021-04-15,To prevent pregnancyDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214154,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-nextstellis
2021,17,Jemperli,dostarlimab-gxly,2021-04-22,To treat endometrial cancerPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761174,https://www.fda.gov/news-events/press-announcements/fda-approves-immunotherapy-endometrial-cancer-specific-biomarker,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-jemperli
2021,18,Zynlonta,loncastuximab tesirine-lpyl,2021-04-23,To treat certain types of relapsed or refractory large B-cell lymphomaDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761196,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-zynlonta
2021,19,Empaveli,pegcetacoplan,2021-05-14,To treat paroxysmal nocturnal hemoglobinuriaDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=215014,,
2021,20,Rybrevant,amivantamab-vmjw,2021-05-21,To treat a subset of non-small cell lung cancerDrug Trials SnapshotPress Release,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761210,https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-subset-non-small-cell-lung-cancer,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-rybrevant
2021,21,Pylarify,piflufolastat F 18,2021-05-26,To identify prostate-specific membrane antigen-positive lesions in prostate cancerDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214793,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-pylarify
2021,22,Lumakras,sotorasib,2021-05-28,To treat types of non-small cell lung cancer Press ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214665,https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-lung-cancer-mutation-previously-considered-resistant-drug,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-lumakras
2021,23,Truseltiq,infigratinib,2021-05-28,To treat cholangiocarcinoma whose disease meets certain criteriaDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214622,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-truseltiq
2021,24,Lybalvi,olanzapine and samidorphan,2021-05-28,To treat schizophrenia and certain aspects of bipolar I disorderDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=213378,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-lybalvi
2021,25,Brexafemme,ibrexafungerp,2021-06-01,To treat vulvovaginal candidiasisDrug Trials Snapshots,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214900,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-brexafemme
2021,26,Aduhelm,aducanumab-avwa,2021-06-07,To treat Alzheimer’s diseasePress ReleaseDrug Trials Snapshots,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761178,https://www.fda.govhttps://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-drug,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-aduhelm
2021,27,Rylaze,asparaginase erwinia chrysanthemi (recombinant)-rywn,2021-06-30,"To treat acute lymphoblastic leukemia and lymphoblastic lymphoma in patients who are allergic to E. coli-derived asparaginase products, as a component of a chemotherapy regimenPress ReleaseDrug Trials Snapshots",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761179,https://www.fda.gov/news-events/press-announcements/fda-approves-component-treatment-regimen-most-common-childhood-cancer,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-rylaze
2021,28,Kerendia,finerenone,2021-07-09,To reduce the risk of kidney and heart complications in chronic kidney disease associated with type 2 diabetesDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215341s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-kerendia
2021,29,Fexinidazole,fexinidazole,2021-07-16,To treat human African trypanosomiasis caused by the parasite Trypanosoma brucei gambienseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214429,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-fexinidazole
2021,30,Rezurock,belumosudil,2021-07-16,To treat chronic graft-versus-host disease after failure of at least two prior lines of systemic therapyDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214783,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-rezurock
2021,31,Bylvay,odevixibat,2021-07-20,To treat pruritusDrug Trials Snapshots,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=215498,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-bylvay
2021,32,Saphnelo,anifrolumab-fnia,2021-07-30,To treat moderate-to severe systemic lupus erythematousus along with standard therapyDrug Trials Snapshots,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761123s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-saphnelo
2021,33,Nexviazyme,avalglucosidase alfa-ngpt,2021-08-06,To treat late-onset Pompe diseasePress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761194,https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-pompe-disease,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-nexviazyme
2021,34,Welireg,belzutifan,2021-08-13,To treat von Hippel-Lindau disease under certain conditionsDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=215383,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-welireg
2021,35,Korsuva,difelikefalin,2021-08-23,To treat moderate-to-severe pruritus associated with chronic kidney disease in certain populationsDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214916,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-korsuva
2021,36,Skytrofa,lonapegsomatropin-tcgd,2021-08-25,To treat short stature due to inadequate secretion of endogenous growth hormoneDrug Trial Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761177,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-skytrofa
2021,37,Exkivity,mobocertinib,2021-09-15,To treat locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutationsDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215310s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-exkivity
2021,38,Tivdak,tisotumab vedotin-tftv,2021-09-20,To treat recurrent or metastatic cervical cancer with disease progression on or after chemotherapyDrug Trial Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761208,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-tivdak
2021,39,Qulipta,atogepant,2021-09-28,To prevent episodic migrainesDrug Trial Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=215206,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-qulipta
2021,40,Livmarli,maralixibat,2021-09-29,To treat cholestatic pruritus associated with Alagille syndromeDrug Trial Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214662,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-livmarli
2021,41,Tavneos,avacopan,2021-10-07,"To treat severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis) in combination with standard therapy, including glucocorticoidsDrug Trial Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214487,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-tavneos
2021,42,Scemblix,asciminib,2021-10-29,To treat Philadelphia chromosome-positive chronic myeloid leukemia with disease that meets certain criteriaDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215358s000Orig1lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-scemblix
2021,43,Besremi,ropeginterferon alfa-2b-njft,2021-11-12,"To treat polycythemia vera, a blood disease that causes the overproduction of red blood cellsPress ReleaseDrug Trials Snapshot",http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761166,https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-rare-blood-disease,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-besremi
2021,44,Voxzogo,vosoritide,2021-11-19,To improve growth in children five years of age and older with achondroplasia and open epiphysesPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214938,https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-improve-growth-children-most-common-form-dwarfism,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-voxzogo
2021,45,Livtencity,maribavir,2021-11-23,To treat post-transplant cytomegalovirus (CMV) infection/disease that does not respond (with or without genetic mutations that cause resistance) to available antiviral treatment for CMVPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=215596,https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-common-type-post-transplant-infection-resistant-other-drugs,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-livtencity
2021,46,Cytalux,pafolacianine,2021-11-29,To help identify ovarian cancer lesions Press ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214907,https://www.fda.gov/news-events/press-announcements/fda-approves-new-imaging-drug-help-identify-ovarian-cancer-lesions,
2021,47,Tezspire,tezepelumab-ekko,2021-12-17,To treat severe asthma as an add-on maintenance therapyDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761224,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-tezspire
2021,48,Vyvgart,efgartigimod alfa-fcab,2021-12-17,To treat generalized myasthenia gravisPress ReleaseDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761195,https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-myasthenia-gravis,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-vyvgart
2021,49,Leqvio,inclisiran,2021-12-22,To treat heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease as an add-on therapyDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=214012,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-leqvio
2021,50,Adbry,tralokinumab-ldrm,2021-12-27,To treat moderate-to-severe atopic dermatitisDrug Trials Snapshot,http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761180,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-adbry
2022,1,Quviviq,daridorexant,2022-01-07,To treat insomniaDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214985s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-quviviq
2022,2,Cibinqo,abrocitinib,2022-01-14,"To treat refractory, moderate-to-severe atopic dermatitisDrug Trials Snapshot",https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213871,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-cibinqo
2022,3,Kimmtrak,tebentafusp-tebn,2022-01-25,To treat unresectable or metastatic uveal melanomaDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761228s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-kimmtrak
2022,4,Vabysmo,faricimab-svoa,2022-01-28,To treat neovascular (wet) aged-related macular degeneration and diabetic macular edemaDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761235s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-vabysmo
2022,5,Enjaymo,sutimlimab-jome,2022-02-04,To decrease the need for red blood cell transfusion due to hemolysis in cold agglutinin diseaseDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761164s000lbl.pdf?utm_medium=email&utm_source=govdelivery,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-enjaymo
2022,6,Pyrukynd,mitapivat,2022-02-17,To treat hemolytic anemia in pyruvate kinase deficiencyDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216196s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-pyrukynd
2022,7,Vonjo,pacritinib,2022-02-28,To treat intermediate or high-risk primary or secondary myelofibrosis in adults with low platelets,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208712s000lbl.pdf,,
2022,8,Ztalmy,ganaxolone,2022-03-18,To treat seizures in cyclin-dependent kinase-like 5 deficiency disorderDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215904s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-ztalmy
2022,9,Opdualag,nivolumab and relatlimab-rmbw,2022-03-18,To treat unresectable or metastatic melanomaDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761234s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-opdualag
2022,10,Pluvicto,lutetium (177Lu) vipivotide tetraxetan,2022-03-23,To treat prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer following other therapiesDrug Trials Snapshot,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215833,,https://www.fda.gov/drugs/drug-safety-and-availability/drug-trials-snapshots-pluvicto
2022,11,Vivjoa,oteseconazole,2022-04-26,To reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are not of reproductive potentialDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215888s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-vivjoa
2022,12,Camzyos,mavacamten,2022-04-28,To treat certain classes of obstructive hypertrophic cardiomyopathyDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214998s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-camzyos
2022,13,Voquezna,"vonoprazan, amoxicillin, and clarithromycin",2022-05-03,To treat Helicobacter pylori infectionDrug Trials Snapshot,https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215152,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-voquezna-triple-pak-voquezna-dual-pak
2022,14,Mounjaro,tirzepatide,2022-05-13,"To improve blood sugar control in diabetes, in addition to diet and exercise Press ReleaseDrug Trials Snapshot",https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215866,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-mounjaro
2022,15,Vtama,tapinarof,2022-05-23,To treat plaque psoriasisDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215272s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-vtama
2022,16,Amvuttra,vutrisiran,2022-06-13,To treat polyneuropathy of hereditary transthyretin-mediated amyloidosisDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215515s000lbl.pdf,,
2022,17,Xenpozyme,Olipudase alfa,2022-08-31,To treat Acid Sphingomyelinase DeficiencyPress ReleaseDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761261s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-xenpozyme
2022,18,Spevigo,spesolimab-sbzo,2022-09-01,To treat generalized pustular psoriasis flaresDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761244s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-spevigo
2022,19,Daxxify,daxibotulinumtoixnA-lanm,2022-09-07,To treat moderate-to-severe glabellar lines associated with corrugator and/or procerus muscle activityDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761127s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-daxxify
2022,20,Sotyktu,deucravacitinib,2022-09-09,To treat moderate-to-severe plaque psoriasisDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214958s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-sotyktu
2022,21,Rolvedon,eflapegrastim,2022-09-09,To decrease the incidence of infection in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropeniaDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761148Orig1s000Corrected_lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-rolvedon
2022,22,Terlivaz,terlipressin,2022-09-14,To improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney functionDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022231s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-terlivaz
2022,23,Elucirem,gadopiclenol,2022-09-21,"To detect and visualize lesions, together with MRI, with abnormal vascularity in the central nervous system and the bodyDrug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216986s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-elucirem
2022,24,Omlonti,oomidenepag isopropyl ophthalmic solution,2022-09-22,To reduce elevated intraocular pressure in patients with open‑angle glaucoma or ocular hypertensionDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215092s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-omlonti
2022,25,Relyvrio,sodium phenylbutyrate/taurursodiol,2022-09-29,To treat amyotrophic lateral sclerosis (ALS)Press ReleaseDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216660s000lbledt.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-relyvrio
2022,26,Lytgobi,futibatinib,2022-09-30,To treat intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangementsDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801Orig1s000lbledt.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-lytgobi
2022,27,Imjudo,tremelimumab,2022-10-21,To treat unresectable hepatocellular carcinomaDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761289s001lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-imjudo
2022,28,Tecvayli,teclistamab-cqyv,2022-10-25,To treat relapsed or refractory multiple myeloma among adults who have received at least four specific lines of therapyDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761291s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-tecvayli
2022,29,Elahere,mirvetuximab soravtansine-gynx,2022-11-14,To treat patients with recurrent ovarian cancer that is resistant to platinum therapyDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761310s000lbl.pdf,,
2022,30,Tzield,teplizumab-mzwv,2022-11-18,To delay the onset of stage 3 type 1 diabetesPress Release,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761183s000lbl.pdf,,
2022,31,Rezlidhia,olutasidenib,2022-12-01,To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutationDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215814s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-rezlidhia
2022,32,Krazati,adagrasib,2022-12-12,To treat KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer in adults who have received at least one prior systemic therapyDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216340s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-krazati
2022,33,Sunlenca,lenacapavir,2022-12-22,"To treat adults with HIV whose HIV infections cannot be successfully treated with other available treatments due to resistance, intolerance, or safety considerationsPress ReleaseDrug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215973s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-sunlenca
2022,34,Lunsumio,mosunetuzumab-axgb,2022-12-22,"To treat adults with relapsed or refractory follicular lymphoma, a type of non-Hodgkin lymphomaDrug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761263s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-lunsumio
2022,35,Xenoview,hyperpolarized Xe-129,2022-12-23,To evaluate pulmonary function and imagingDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214375s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-xenoview
2022,36,Briumvi,ublituximab-xiiy,2022-12-28,To treat relapsing forms of multiple sclerosisDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761238s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-briumvi
2022,37,NexoBrid,anacaulase-bcdb,2022-12-28,To remove eschar in adults with deep partial thickness or full thickness thermal burnsDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761192s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-nexobrid
2023,1,Leqembi,lecanemab-irmb,2023-01-06,To treat Alzheimer’s diseasePress Release,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761269Orig1s000lbl.pdf,https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-disease-treatment,
2023,2,Brenzavvy,bexagliflozin,2023-01-20,To improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exerciseDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214373s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-brenzavvy
2023,3,Jaypirca,pirtobrutinib,2023-01-27,"To treat relapsed or refractory mantle cell lymphoma in adults who have had at least two lines of systemic therapy, including a BTK inhibitorDrug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216059Orig1s000Corrected_lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-jaypirca
2023,4,Orserdu,elacestrant,2023-01-27,"To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapyDrug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-orserdu
2023,5,Jesduvroq,daprodustat,2023-02-01,To treat anemia caused by chronic kidney disease for adults on dialysis for at least four monthsPress ReleaseDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216951s000lbl.pdf,https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-treatment-anemia-caused-chronic-kidney-disease-adults-dialysis,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-jesduvroq
2023,6,Lamzede,velmanase alfa-tycv,2023-02-16,To treat non-central nervous system manifestations of alpha-mannosidosis,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761278s000lbl.pdf,,
2023,7,Filspari,sparsentan,2023-02-17,To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progressionDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216403s000lbl.pdf,,https://www.fda.govhttps://www.fda.gov/drugs/drug-trials-snapshots-filspari
2023,8,Skyclarys,omaveloxolone,2023-02-28,To treat Friedrich’s ataxiaDrug Trials Snapshots,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216718Orig1s000lbl.pdf,,https://www.fda.gov/drugs/development-approval-process-drugs/drug-trials-snapshots-skyclarys
2023,9,Zavzpret,zavegepant,2023-03-09,To treat migraine,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216386s000lbl.pdf,,
2023,10,Daybue,trofinetide,2023-03-10,To treat Rett syndrome,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217026s000lbl.pdf,,
2023,11,Zynyz,retifanlimab-dlwr,2023-03-22,To treat metastatic or recurrent locally advanced Merkel cell carcinoma,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761334s000lbl.pdf,,
2023,12,Rezzayo,rezafungin,2023-03-22,To treat candidemia and invasive candidiasis,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217417s000lbl.pdf,,
2023,13,Joenja,leniolisib,2023-03-24,To treat activated phosphoinositide 3-kinase delta syndromeDrug Trials Snapshots,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217759s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-joenja
2023,14,Qalsody,tofersen,2023-04-25,To treat amyotrophic lateral sclerosis in adults who have a SOD1 gene mutation,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215887s000lbl.pdf,,
2023,15,Elfabrio,pegunigalsidase alfa-iwxj,2023-05-09,To treat confirmed Fabry disease,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761161s000lbl.pdf,,
2023,16,Veozah,fezolinetant,2023-05-12,To treat moderate to severe hot flashes caused by menopausePress Release,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216578s000lbl.pdf,https://www.fda.gov/news-events/press-announcements/fda-approves-novel-drug-treat-moderate-severe-hot-flashes-caused-menopause,
2023,17,Miebo,perfluorhexyloctane,2023-05-18,To treat signs and symptoms of dry eye disease,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216675s000lbl.pdf,,
2023,18,Epkinly,epcoritamab-bysp,2023-05-19,To treat relapsed or refractory diffuse large B-cell lymphoma (not otherwise specified) and high-grade B-cell lymphoma after two or more lines of systemic therapy,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761324s000lbl.pdf,,
2023,19,Xacduro,"sulbactam, durlobactam",2023-05-23,To treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complexPress Release,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216974Orig1s000Correctedlbl.pdf,https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-pneumonia-caused-certain-difficult-treat-bacteria,
2023,20,Paxlovid,"nirmatrelvir, ritonavir",2023-05-25,To treat mild-to-moderate COVID-19 in adults at high risk for progression to severe COVID-19Press ReleaseDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217188s000lbl.pdf,https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-antiviral-treatment-covid-19-adults,https://www.fda.gov/drugs/development-approval-process-drugs/drug-trials-snapshots-paxlovid
2023,21,Posluma,flotufolastat F 18,2023-05-25,To use with positron emission tomography imaging in certain patients with prostate cancerDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216023s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-posluma
2023,22,Inpefa,sotagliflozin,2023-05-26,​To treat heart failure,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216203s000lbl.pdf,,
2023,23,Columvi,glofitamab-gxbm,2023-06-15,"To treat diffuse large B-cell lymphoma, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma after two or more lines of systemic therapyDrug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761309s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-columvi
2023,24,Litfulo,ritlecitinib,2023-06-23,To treat severely patchy hair lossDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215830s000lbl.pdf,,https://www.fda.gov/drugs/development-approval-process-drugs/drug-trials-snapshots-litfulo
2023,25,Rystiggo,rozanolixizumab-noli,2023-06-26,To treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor- or anti-muscle-specific tyrosine kinase antibody-positiveDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761286s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-rystiggo
2023,26,Ngenla,somatrogon-ghla,2023-06-27,To treat growth failure due to inadequate secretion of endogenous growth hormoneDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761184Orig1s000Corrected_lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-ngenla
2023,27,Beyfortus,nirsevimab-alip,2023-07-17,To prevent respiratory syncytial virus (RSV) lower respiratory tract diseasePress ReleaseDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761328s000lbl.pdf,https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-prevent-rsv-babies-and-toddlers,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-beyfortus
2023,28,Vanflyta,quizartinib,2023-07-20,To use as part of a treatment regimen for newly diagnosed acute myeloid leukemia that meets certain criteriaDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216993s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-vanflyta
2023,29,Xdemvy,lotilaner,2023-07-25,To treat Demodex blepharitis,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217603s000lbl.pdf,,
2023,30,Zurzuvae,zuranolone,2023-08-04,To treat postpartum depression Press ReleaseDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217369s000lbl.pdf,https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-treatment-postpartum-depression,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-zurzuvae
2023,31,Izervay,avacincaptad pegol,2023-08-04,To treat geographic atrophy secondary to age-related macular degeneration,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217225s000lbl.pdf,,
2023,32,Talvey,talquetamab-tgvs,2023-08-09,To treat adults with relapsed or refractory multiple myeloma who have received at least four prior therapies,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761342s000lbl.pdf,,
2023,33,Elrexfio,elranatamab-bcmm,2023-08-14,To treat adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761345Orig1s000lbl.pdf,,
2023,34,Sohonos,palovarotene,2023-08-16,To reduce the volume of new heterotopic ossification in adults and pediatric patients (aged 8 years and older for females and 10 years and older for males) with fibrodysplasia ossificans progressiva,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215559s000lbl.pdf,,
2023,35,Veopoz,pozelimab-bbfg,2023-08-18,"To treat patients 1 year old and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761339s000lbl.pdf,,
2023,36,Aphexda,motixafortide,2023-09-08,To use with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myelomaDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217159s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-aphexda
2023,37,Ojjaara,momelotinib,2023-09-15,To treat intermediate or high-risk myelofibrosis in adults with anemia,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216873s000lbl.pdf,,
2023,38,Exxua,gepirone,2023-09-22,To treat major depressive disorder,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021164s000lbl.pdf,,
2023,39,Pombiliti,cipaglucosidase alfa-atga,2023-09-28,To treat late-onset Pompe diseaseDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761204s000lbl.pdf,,https://www.fda.gov/drugs/development-approval-process-drugs/drug-trials-snapshots-pombiliti
2023,40,Rivfloza,nedosiran,2023-09-29,To lower urinary oxalate levels in patients 9 years and older with primary hyperoxaluria type 1 and relatively preserved kidney functionDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215842s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-rivfloza
2023,41,Velsipity,etrasimod,2023-10-12,To treat moderately to severely active ulcerative colitis in adults,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216956s000lbl.pdf,,
2023,42,Zilbrysq,zilucoplan,2023-10-17,To treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody positive,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216834s000lbl.pdf,,
2023,43,Bimzelx,bimekizumab,2023-10-17,To treat moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapyDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761151s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-bimzelx
2023,44,Agamree,vamorolone,2023-10-26,To treat Duchenne muscular dystrophyDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215239s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-agamree
2023,45,Omvoh,mirikizumab-mrkz,2023-10-26,To treat ulcerative colitis,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761279s000lbl.pdf,,
2023,46,Loqtorzi,toripalimab-tpzi,2023-10-27,To treat recurrent or metastatic nasopharyngeal carcinoma when used together with or following other therapies,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761240s000lbl.pdf,,
2023,47,Fruzaqla,fruquintinib,2023-11-08,"To treat refractory, metastatic colorectal cancerDrug Trials Snapshot",https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217564s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-fruzaqla
2023,48,Defencath,"taurolidine, heparin",2023-11-15,To reduce the incidence of catheter-related bloodstream infections in adults with kidney failure receiving chronic hemodialysis through a central venous catheter,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214520s000lbl.pdf,,
2023,49,Augtyro,repotrectinib,2023-11-15,To treat ROS1-positive non-small cell lung cancerDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218213s000lbl.pdf,,https://www.fda.gov/drugs/development-approval-process-drugs/drug-trials-snapshots-augtyro
2023,50,Ryzneuta,efbemalenograstim alfa-vuxw,2023-11-16,To treat neutropeniaDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761134s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-ryzneuta
2023,51,Truqap,capivasertib,2023-11-16,To treat breast cancer that meets certain disease criteria,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf,,
2023,52,Ogsiveo,nirogacestat,2023-11-27,To treat adults with progressing desmoid tumors who require systemic treatmentDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217677s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-ogsiveo
2023,53,Fabhalta,iptacopan,2023-12-05,To treat paroxysmal nocturnal hemoglobinuria,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218276s000lbl.pdf,,
2023,54,Filsuvez,birch triterpenes,2023-12-18,To treat wounds associated with dystrophic and junctional epidermolysis bullosaDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215064s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-filsuvez
2023,55,Wainua,eplontersen,2023-12-21,To treat polyneuropathy of hereditary transthyretin-mediated amyloidosisDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217388s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-wainua
2024,1,Zelsuvmi,berdazimer,2024-01-05,To treat molluscum contagiosumDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217424s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-zelsuvmi
2024,2,Exblifep,"cefepime, enmetazobactam",2024-02-22,To treat complicated urinary tract infections,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216165s000lbl.pdf,,
2024,3,Letybo,letibotulinumtoxinA-wlbg,2024-02-29,To temporarily improve the appearance of moderate-to-severe glabellar linesDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761225s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-letybo
2024,4,Tevimbra,tislelizumab-jsgr,2024-03-13,To treat unresectable or metastatic esophageal squamous cell carcinomaDrug Trials Snapshot,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761232Orig1s000lbl.pdf,,https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-tevimbra
2024,5,Rezdiffra,resmetirom,2024-03-14,To treat noncirrhotic non-alcoholic steatohepatitis with moderate to advanced liver scarringPress Release,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217785s000lbl.pdf,https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease,
2024,6,Tryvio,aprocitentan,2024-03-19,To treat hypertension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217686s000lbl.pdf,,
2024,7,Duvyzat,givinostat,2024-03-21,To treat Duchenne muscular dystrophy in individuals aged 6 years and olderPress Release,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217865Orig1s000lbl.pdf,https://www.fda.gov/news-events/press-announcements/fda-approves-nonsteroidal-treatment-duchenne-muscular-dystrophy,
2024,8,Winrevair,sotatercept-csrk,2024-03-26,To treat pulmonary arterial hypertension,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761363s000lbl.pdf,,
2024,9,Vafseo,vadadustat,2024-03-27,To treat anemia due to chronic kidney disease,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215192s000lbl.pdf,,
2024,10,Voydeya,danicopan,2024-03-29,To treat extravascular hemolysis with paroxysmal nocturnal hemoglobinuria,,,
2024,11,Zevtera,ceftobiprole medocaril sodium,2024-04-03,"To treat certain bloodstream infections, bacterial skin and associated tissue infections, and community-acquired bacterial pneumoniaPress Release",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218275s000lbl.pdf,https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibiotic-three-different-uses,
2024,12,Lumisight,pegulicianine,2024-04-17,To use as an optical imaging agent for the detection of cancerous tissue,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214511s000lbl.pdf,,
2024,13,Anktiva,nogapendekin alfa inbakicept-pmln,2024-04-22,To treat bladder cancer,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761336s000lbl.pdf,,
2024,14,Ojemda,tovorafenib,2024-04-23,To treat relapsed or refractory pediatric low-grade glioma,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218033s000lbl.pdf,,
2024,15,Xolremdi,mavorixafor,2024-04-26,"To treat WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis)",https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218709s000lbl.pdf,,
2024,16,Imdelltra,tarlatamab-dlle,2024-05-16,To treat extensive stage small cell lung cancer,https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761344s000lbl.pdf,,
